Antigenic	O
specificities	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
lesions	O
.	O

Lesions	O
resulting	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infection	O
are	O
characterized	O
by	O
infiltration	O
of	O
CD4+	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O

Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B-protein
truncated	I-protein
glycoprotein	I-protein
B	I-protein
(	O
gB	B-protein
)	O
or	O
gD	B-protein
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV-specific	B-cell_line
clones	I-cell_line
isolated	O
from	O
lesions	O
.	O

The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O

The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B-protein
antigens	I-protein
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O

The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O

Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O

The	O
antigenic	O
specificities	O
of	O
lesion-derived	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O

Human	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
reactive	O
with	O
gC	B-protein
and	O
VP16	B-protein
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O

or	NULL
ViroLoGy	NULL
,	NULL
May	NULL
1994	NULL
,	NULL
p.	NULL
2803-2810	NULL
0022-538	NULL
X	NULL
,	NULL
/94/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1994	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

68	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Antigenic	NULL
Specificities	NULL
of	NULL
Human	NULL
CD4*	NULL
T-Cell	NULL
Clones	NULL
Recovered	NULL
from	NULL
Recurrent	NULL
Genital	NULL
Herpes	NULL
Simplex	NULL
Virus	NULL
Type	NULL
2	NULL
Lesions	NULL
DAVID	NULL
M.	NULL
KOELLE	NULL
,	NULL
'*	NULL
LAWRENCE	NULL
COREY	NULL
,	NULL
``	NULL
RAE	NULL
LYN	NULL
BURKE	NULL
,	NULL
``	NULL
ROSELYN	NULL
J.	NULL
EISENBERG	NULL
,	NULL
``	NULL
GARY	NULL
H.	NULL
COHEN	NULL
,	NULL
``	NULL
RATH	NULL
PICHYANGKURA	NULL
,	NULL
*	NULL
anp	NULL
STEVEN	NULL
J.	NULL
TRIEZENBERG®*	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98195	NULL
;	NULL
Chiron	NULL
Corporation	NULL
,	NULL
Emeryville	NULL
,	NULL
California	NULL
94608	NULL
``	NULL
;	NULL
University	NULL
of	NULL
Pennsylvania	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pennsylvania	NULL
19104	NULL
``	NULL
;	NULL
and	NULL
Michigan	NULL
State	NULL
University	NULL
,	NULL
East	NULL
Lansing	NULL
,	NULL
Michigan	NULL
48824°	NULL
Received	NULL
22	NULL
November	NULL
1993/Accepted	NULL
24	NULL
January	NULL
1994	NULL
Lesions	NULL
resulting	NULL
from	NULL
recurrent	NULL
genital	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
infection	NULL
are	NULL
characterized	NULL
by	NULL
infiltration	NULL
of	NULL
CD4*	NULL
lymphocytes	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
the	NULL
antigenic	NULL
specificity	NULL
of	NULL
47	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
recovered	NULL
from	NULL
the	NULL
HSV-2	NULL
buttock	NULL
and	NULL
thigh	NULL
lesions	NULL
of	NULL
five	NULL
patients	NULL
.	NULL

Clones	NULL
with	NULL
proliferative	NULL
responses	NULL
to	NULL
recombinant	NULL
truncated	NULL
glycoprotein	NULL
B	NULL
(	NULL
gB	NULL
)	NULL
or	NULL
gD	NULL
of	NULL
HSV-2	NULL
or	NULL
purified	NULL
natural	NULL
gC	NULL
of	NULL
HSV-2	NULL
comprised	NULL
a	NULL
minority	NULL
of	NULL
the	NULL
total	NULL
number	NULL
of	NULL
HSV-specific	NULL
clones	NULL
isolated	NULL
from	NULL
lesions	NULL
.	NULL

The	NULL
gC2-	NULL
and	NULL
gD2-specific	NULL
CD4*	NULL
clones	NULL
had	NULL
cytotoxic	NULL
activity	NULL
.	NULL

The	NULL
approximate	NULL
locations	NULL
of	NULL
the	NULL
HSV-2	NULL
genes	NULL
encoding	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
antigens	NULL
have	NULL
been	NULL
determined	NULL
by	NULL
using	NULL
HSV-1	NULL
X	NULL
HSV-2	NULL
intertypic	NULL
recombinant	NULL
virus	NULL
and	NULL
include	NULL
the	NULL
approximate	NULL
map	NULL
regions	NULL
0.30	NULL
to	NULL
0.46	NULL
,	NULL
0.59	NULL
to	NULL
0.67	NULL
,	NULL
0.67	NULL
to	NULL
0.73	NULL
,	NULL
and	NULL
0.82	NULL
to	NULL
1.0	NULL
map	NULL
units	NULL
.	NULL

The	NULL
antigenic	NULL
specificity	NULL
of	NULL
an	NULL
HLA	NULL
DQ2-restricted	NULL
,	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clone	NULL
was	NULL
mapped	NULL
to	NULL
amino	NULL
acids	NULL
425	NULL
to	NULL
444	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
by	NULL
sequential	NULL
use	NULL
of	NULL
an	NULL
intertypic	NULL
recombinant	NULL
virus	NULL
containing	NULL
VP16	NULL
of	NULL
HSV-2	NULL
in	NULL
an	NULL
HSV-1	NULL
background	NULL
,	NULL
recombinant	NULL
VP16	NULL
fusion	NULL
proteins	NULL
,	NULL
and	NULL
synthetic	NULL
peptides	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
remaining	NULL
four	NULL
patients	NULL
also	NULL
yielded	NULL
at	NULL
least	NULL
one	NULL
type-specific	NULL
T-cell	NULL
clone	NULL
reactive	NULL
with	NULL
an	NULL
HSV-2	NULL
epitope	NULL
mapping	NULL
to	NULL
approximately	NULL
0.67	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
.	NULL

The	NULL
antigenic	NULL
specificities	NULL
of	NULL
lesion-derived	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
are	NULL
quite	NULL
diverse	NULL
and	NULL
include	NULL
at	NULL
least	NULL
10	NULL
epitopes	NULL
.	NULL

Human	NULL
T-cell	NULL
clones	NULL
reactive	NULL
with	NULL
gC	NULL
and	NULL
VP16	NULL
are	NULL
reported	NULL
here	NULL
for	NULL
the	NULL
first	NULL
time	NULL
.	NULL

Recurrent	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
infection	NULL
in	NULL
humans	NULL
is	NULL
a	NULL
localized	NULL
cutaneous	NULL
disease	NULL
in	NULL
individuals	NULL
with	NULL
intact	NULL
cellular	NULL
immunity	NULL
.	NULL

The	NULL
roles	NULL
of	NULL
infiltrating	NULL
cells	NULL
in	NULL
host	NULL
defense	NULL
are	NULL
incompletely	NULL
understood	NULL
.	NULL

The	NULL
cellular	NULL
infiltrate	NULL
is	NULL
enriched	NULL
for	NULL
CD4*	NULL
cells	NULL
during	NULL
early	NULL
stages	NULL
of	NULL
lesion	NULL
formation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
murine	NULL
models	NULL
of	NULL
HSV	NULL
infection	NULL
,	NULL
adoptively	NULL
transferred	NULL
bulk	NULL
(	NULL
28	NULL
)	NULL
or	NULL
cloned	NULL
(	NULL
24	NULL
)	NULL
CD4*	NULL
T	NULL
cells	NULL
can	NULL
protect	NULL
against	NULL
viral	NULL
challenge	NULL
.	NULL

Keratinocytes	NULL
,	NULL
the	NULL
predominant	NULL
infected	NULL
cell	NULL
type	NULL
in	NULL
HSV	NULL
skin	NULL
lesions	NULL
,	NULL
are	NULL
capable	NULL
of	NULL
presenting	NULL
HSV	NULL
antigen	NULL
to	NULL
CD4*	NULL
T	NULL
cells	NULL
after	NULL
gamma	NULL
interferon	NULL
treatment	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Functional	NULL
roles	NULL
of	NULL
lesion-infiltrating	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
recurrent	NULL
HSV	NULL
lesions	NULL
may	NULL
include	NULL
lymphokine	NULL
release	NULL
,	NULL
inhibition	NULL
of	NULL
viral	NULL
replication	NULL
,	NULL
cytotoxicity	NULL
,	NULL
and	NULL
B-cell	NULL
help	NULL
(	NULL
48-50	NULL
)	NULL
.	NULL

The	NULL
antigens	NULL
recognized	NULL
by	NULL
human	NULL
HSV-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
characterized	NULL
.	NULL

The	NULL
membrane	NULL
glycoproteins	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
(	NULL
gB	NULL
,	NULL
gC	NULL
,	NULL
and	NULL
gD	NULL
)	NULL
stimulate	NULL
proliferation	NULL
of	NULL
T	NULL
lymphocytes	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
of	NULL
HSV-seropositive	NULL
individuals	NULL
(	NULL
43	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
of	NULL
PBMC	NULL
with	NULL
HSV	NULL
antigen	NULL
has	NULL
been	NULL
required	NULL
to	NULL
expand	NULL
and	NULL
enrich	NULL
HSV-specific	NULL
T	NULL
cells	NULL
prior	NULL
to	NULL
derivation	NULL
of	NULL
HSV	NULL
-specific	NULL
T-cell	NULL
clones	NULL
(	NULL
51	NULL
)	NULL
.	NULL

A	NULL
large	NULL
proportion	NULL
of	NULL
the	NULL
T-cell	NULL
clones	NULL
isolated	NULL
and	NULL
maintained	NULL
by	NULL
periodic	NULL
restimulation	NULL
with	NULL
whole	NULL
HSV	NULL
antigen	NULL
were	NULL
reactive	NULL
with	NULL
gB	NULL
or	NULL
gD	NULL
(	NULL
52	NULL
)	NULL
,	NULL
and	NULL
a	NULL
substantial	NULL
proportion	NULL
of	NULL
these	NULL
clones	NULL
also	NULL
had	NULL
cytotoxic	NULL
T-lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
activity	NULL
(	NULL
48	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
crude	NULL
viral	NULL
antigen	NULL
influences	NULL
the	NULL
relative	NULL
proportions	NULL
of	NULL
resultant	NULL
clones	NULL
reactive	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Pacific	NULL
Medical	NULL
Center	NULL
,	NULL
Room	NULL
9301	NULL
,	NULL
1200	NULL
12th	NULL
Ave.	NULL
S.	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98144	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
206	NULL
)	NULL
326-4162	NULL
(	NULL
laboratory	NULL
)	NULL
;	NULL
(	NULL
206	NULL
)	NULL
326-4177	NULL
(	NULL
office	NULL
)	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
206	NULL
)	NULL
326-4178	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
viralimm	NULL
@	NULL
u.washington.edu	NULL
.	NULL

2803	NULL
with	NULL
specific	NULL
HSV	NULL
proteins	NULL
or	NULL
displaying	NULL
CTL	NULL
or	NULL
other	NULL
effector	NULL
functions	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
recognize	NULL
primarily	NULL
exogenously	NULL
synthesized	NULL
antigen	NULL
after	NULL
processing	NULL
by	NULL
appropriate	NULL
antigen-processing	NULL
cells	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Abundant	NULL
virion	NULL
proteins	NULL
are	NULL
thus	NULL
candidates	NULL
for	NULL
CD4*	NULL
T-cell	NULL
antigens	NULL
.	NULL

Strong	NULL
serum	NULL
antibody	NULL
responses	NULL
to	NULL
viral	NULL
glycoproteins	NULL
and	NULL
the	NULL
abundant	NULL
tegument	NULL
protein	NULL
VP16	NULL
are	NULL
present	NULL
in	NULL
human	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
infections	NULL
(	NULL
1	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
CD4*	NULL
helper	NULL
T-cell	NULL
response	NULL
.	NULL

However	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
human	NULL
CD4*	NULL
response	NULL
to	NULL
VP16	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
demonstrated	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
developed	NULL
techniques	NULL
for	NULL
isolating	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
from	NULL
recurrent	NULL
human	NULL
HSV	NULL
lesions	NULL
(	NULL
23	NULL
)	NULL
.	NULL

We	NULL
report	NULL
here	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
antigens	NULL
recognized	NULL
by	NULL
a	NULL
subset	NULL
of	NULL
these	NULL
T-cell	NULL
clones	NULL
and	NULL
the	NULL
mapping	NULL
of	NULL
additional	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
T-cell	NULL
antigens	NULL
with	NULL
the	NULL
use	NULL
of	NULL
HSV-1	NULL
x	NULL
HSV-2	NULL
intertypic	NULL
recombinant	NULL
viruses	NULL
(	NULL
IRV	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Viruses	NULL
.	NULL

HSV-2	NULL
strain	NULL
333	NULL
(	NULL
22	NULL
)	NULL
and	NULL
HSV-1	NULL
strain	NULL
E115	NULL
(	NULL
40	NULL
)	NULL
were	NULL
used	NULL
throughout	NULL
unless	NULL
otherwise	NULL
specified	NULL
.	NULL

HSV-1	NULL
%	NULL
HSV-2	NULL
IRV	NULL
RH1G7	NULL
,	NULL
RS1G25	NULL
,	NULL
RS1G31	NULL
,	NULL
and	NULL
R7015	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
were	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
Bernard	NULL
Roizman	NULL
,	NULL
.	NULL

HSV-1	NULL
strain	NULL
MP801-1	NULL
,	NULL
expressing	NULL
the	NULL
gene	NULL
for	NULL
gC	NULL
of	NULL
HSV-2	NULL
,	NULL
and	NULL
HSV-2	NULL
strain	NULL
GpS1	NULL
,	NULL
containing	NULL
a	NULL
deletion	NULL
of	NULL
gC	NULL
,	NULL
were	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
Patricia	NULL
Spear	NULL
(	NULL
53	NULL
)	NULL
.	NULL

An	NULL
IRV	NULL
(	NULL
designated	NULL
RP-2	NULL
)	NULL
bearing	NULL
the	NULL
VP16	NULL
gene	NULL
from	NULL
HSV-2	NULL
(	NULL
strain	NULL
HG52	NULL
)	NULL
in	NULL
the	NULL
HSV-1	NULL
(	NULL
KOS	NULL
)	NULL
genome	NULL
was	NULL
constructed	NULL
by	NULL
complementation	NULL
of	NULL
the	NULL
VP16-deleted	NULL
virus	NULL
SMA	NULL
(	NULL
45	NULL
)	NULL
.	NULL

The	NULL
HSV-2	NULL
fragment	NULL
includes	NULL
the	NULL
entire	NULL
VP16	NULL
open	NULL
reading	NULL
frame	NULL
with	NULL
30	NULL
bp	NULL
of	NULL
5	NULL
flanking	NULL
sequence	NULL
and	NULL
43	NULL
bp	NULL
of	NULL
3	NULL
'	NULL
flanking	NULL
sequence	NULL
.	NULL

2804	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

Virus	NULL
stocks	NULL
were	NULL
prepared	NULL
by	NULL
infecting	NULL
HDF	NULL
cells	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
0.001	NULL
to	NULL
0.01	NULL
or	NULL
1.0	NULL
(	NULL
strain	NULL
RP-2	NULL
only	NULL
)	NULL
and	NULL
allowing	NULL
the	NULL
infection	NULL
to	NULL
progress	NULL
until	NULL
cytopathic	NULL
effect	NULL
involved	NULL
80	NULL
to	NULL
100	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Scraped	NULL
cells	NULL
were	NULL
sonicated	NULL
and	NULL
then	NULL
centrifuged	NULL
at	NULL
400	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
after	NULL
addition	NULL
of	NULL
2	NULL
ml	NULL
of	NULL
minimal	NULL
essential	NULL
medium-10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
per	NULL
original	NULL
150-cm*	NULL
flask	NULL
of	NULL
HDF	NULL
cells	NULL
.	NULL

Supernatant	NULL
was	NULL
frozen	NULL
in	NULL
aliquots	NULL
,	NULL
and	NULL
virus	NULL
titers	NULL
were	NULL
determined	NULL
by	NULL
a	NULL
plaque	NULL
assay	NULL
on	NULL
Vero	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Titers	NULL
ranged	NULL
from	NULL
10	NULL
``	NULL
to	NULL
3	NULL
x	NULL
10°	NULL
PFU/ml	NULL
.	NULL

Mock	NULL
virus	NULL
preparations	NULL
were	NULL
made	NULL
from	NULL
the	NULL
same	NULL
batch	NULL
of	NULL
HDF	NULL
.	NULL

Recombinant	NULL
vaccinia	NULL
viruses	NULL
containing	NULL
the	NULL
genes	NULL
for	NULL
gB	NULL
and	NULL
gD	NULL
of	NULL
HSV-2	NULL
(	NULL
42	NULL
)	NULL
and	NULL
wild-type	NULL
vaccinia	NULL
virus	NULL
New	NULL
York	NULL
were	NULL
grown	NULL
on	NULL
HDF	NULL
and	NULL
prepared	NULL
in	NULL
the	NULL
same	NULL
fashion	NULL
as	NULL
HSV	NULL
strains	NULL
,	NULL
and	NULL
titers	NULL
were	NULL
determined	NULL
by	NULL
a	NULL
plaque	NULL
assay	NULL
on	NULL
BHK-21	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
.	NULL

PBMC	NULL
were	NULL
prepared	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
and	NULL
cryopreserved	NULL
for	NULL
use	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
.	NULL

Epstein-Barr	NULL
virus-transformed	NULL
lym-phoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCL	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
PBMC	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
42	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
RPMI-FC	NULL
(	NULL
RPMI	NULL
1640	NULL
,	NULL
25	NULL
mM	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
[	NULL
HEPES	NULL
]	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
50	NULL
pug	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
x	NULL
10~°	NULL
M	NULL
B-mercaptoethanol	NULL
,	NULL
1	NULL
mM	NULL
pyruvate	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
.	NULL

HDF	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
minimal	NULL
essential	NULL
medium-10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Cells	NULL
used	NULL
for	NULL
preparation	NULL
of	NULL
viral	NULL
stocks	NULL
and	NULL
functional	NULL
assays	NULL
were	NULL
negative	NULL
for	NULL
mycoplasma	NULL
(	NULL
Mycotect	NULL
;	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

T-lymphocyte	NULL
culture	NULL
.	NULL

Lymphocytes	NULL
recovered	NULL
from	NULL
swabs	NULL
or	NULL
biopsies	NULL
of	NULL
culture-positive	NULL
HSV-2	NULL
lesions	NULL
were	NULL
cloned	NULL
by	NULL
using	NULL
a	NULL
high	NULL
efficiency	NULL
procedure	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
and	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
27	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
vesicle	NULL
fluid	NULL
and	NULL
scraped	NULL
cells	NULL
from	NULL
vesicle	NULL
bases	NULL
,	NULL
or	NULL
cells	NULL
recovered	NULL
from	NULL
3-mm	NULL
skin	NULL
biopsies	NULL
minced	NULL
with	NULL
scissors	NULL
and	NULL
expressed	NULL
through	NULL
a	NULL
190-wm-pore-size	NULL
sieve	NULL
(	NULL
Cel-lector	NULL
;	NULL
Bellco	NULL
Glass	NULL
,	NULL
Inc.	NULL
,	NULL
Vineland	NULL
,	NULL
N.J.	NULL
)	NULL
,	NULL
were	NULL
underlaid	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
Ficoll-Hypaque	NULL
.	NULL

Cells	NULL
were	NULL
recovered	NULL
from	NULL
the	NULL
interface	NULL
after	NULL
centrifugation	NULL
at	NULL
400	NULL
%	NULL
g	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
90	NULL
to	NULL
95	NULL
%	NULL
polymorphonuclear	NULL
leukocytes	NULL
,	NULL
with	NULL
occasional	NULL
eosinophils	NULL
and	NULL
monocytes	NULL
,	NULL
1	NULL
%	NULL
or	NULL
less	NULL
small	NULL
round	NULL
mononuclear	NULL
cells	NULL
,	NULL
and	NULL
5	NULL
to	NULL
10	NULL
%	NULL
epithelial	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
multiple	NULL
nuclei	NULL
or	NULL
inclusions	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
plated	NULL
at	NULL
10	NULL
to	NULL
200	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
T-cell	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
containing	NULL
25	NULL
mM	NULL
HEPES	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
50	NULL
pug	NULL
of	NULL
streptomycin	NULL
per	NULL
mi	NULL
,	NULL
50	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
10	NULL
%	NULL
human	NULL
blood	NULL
type	NULL
AB*	NULL
serum	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
PHA	NULL
,	NULL
allogeneic	NULL
irradiated	NULL
PBMC	NULL
as	NULL
feeder	NULL
cells	NULL
,	NULL
and	NULL
20	NULL
to	NULL
50	NULL
U	NULL
of	NULL
IL-2	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Acyclovir	NULL
(	NULL
50	NULL
mM	NULL
)	NULL
was	NULL
included	NULL
for	NULL
the	NULL
first	NULL
2	NULL
weeks	NULL
to	NULL
inhibit	NULL
HSV	NULL
replication	NULL
.	NULL

Between	NULL
7.9	NULL
and	NULL
48.7	NULL
%	NULL
of	NULL
wells	NULL
were	NULL
positive	NULL
for	NULL
growth	NULL
by	NULL
microscopic	NULL
examination	NULL
.	NULL

Clones	NULL
were	NULL
periodically	NULL
restimu-lated	NULL
with	NULL
PHA	NULL
,	NULL
allogeneic	NULL
feeder	NULL
cells	NULL
,	NULL
and	NULL
IL-2	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Subclones	NULL
were	NULL
derived	NULL
at	NULL
one	NULL
cell	NULL
per	NULL
well	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cells	NULL
(	NULL
4.2	NULL
x	NULL
10°	NULL
)	NULL
recovered	NULL
from	NULL
swabs	NULL
from	NULL
patient	NULL
1	NULL
,	NULL
lesion	NULL
A	NULL
,	NULL
were	NULL
stimulated	NULL
in	NULL
bulk	NULL
with	NULL
10°	NULL
allogeneic	NULL
irradiated	NULL
(	NULL
3,300	NULL
rads	NULL
of	NULL
gamma	NULL
irradiation	NULL
)	NULL
PBMC	NULL
and	NULL
0.4	NULL
ug	NULL
of	NULL
PHA-P	NULL
(	NULL
Murex	NULL
Diagnostics	NULL
Ltd.	NULL
,	NULL
Dartford	NULL
,	NULL
England	NULL
)	NULL
per	NULL
ml	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
T-cell	NULL
medium	NULL
plus	NULL
50	NULL
mM	NULL
acyclovir	NULL
in	NULL
a	NULL
1.88-em*	NULL
well	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
1	NULL
ml	NULL
of	NULL
medium	NULL
was	NULL
exchanged	NULL
for	NULL
medium	NULL
containing	NULL
50	NULL
U	NULL
of	NULL
IL-2	NULL
per	NULL
ml	NULL
.	NULL

Cells	NULL
were	NULL
split	NULL
as	NULL
necessary	NULL
and	NULL
fed	NULL
with	NULL
T-cell	NULL
medium	NULL
containing	NULL
50	NULL
U	NULL
of	NULL
IL-2	NULL
per	NULL
ml	NULL
.	NULL

Clones	NULL
were	NULL
derived	NULL
after	NULL
19	NULL
days	NULL
of	NULL
growth	NULL
by	NULL
plating	NULL
the	NULL
cells	NULL
at	NULL
one	NULL
cell	NULL
per	NULL
well	NULL
with	NULL
allogeneic	NULL
irradiated	NULL
PBMC	NULL
,	NULL
PHA	NULL
,	NULL
and	NULL
IL-2	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Proliferation	NULL
assays	NULL
.	NULL

Screening	NULL
assays	NULL
for	NULL
lesion-derived	NULL
T-cell	NULL
clones	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
as	NULL
described	NULL
previ-	NULL
J.	NULL
ViroL	NULL
.	NULL

ously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Cloned	NULL
T	NULL
cells	NULL
or	NULL
bulk	NULL
lesion-derived	NULL
cells	NULL
(	NULL
10*	NULL
per	NULL
well	NULL
)	NULL
and	NULL
antigen	NULL
were	NULL
added	NULL
to	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
wl	NULL
of	NULL
T-cell	NULL
medium	NULL
in	NULL
96-well	NULL
U-bottom	NULL
Elates	NULL
.	NULL

Autologous	NULL
gam-ma-irradiated	NULL
(	NULL
3,300	NULL
rads	NULL
)	NULL
PBMC	NULL
(	NULL
10°	NULL
per	NULL
well	NULL
)	NULL
were	NULL
included	NULL
as	NULL
APC	NULL
.	NULL

After	NULL
3	NULL
days	NULL
,	NULL
[	NULL
'	NULL
H	NULL
thymidine	NULL
(	NULL
1	NULL
pCi	NULL
per	NULL
well	NULL
)	NULL
was	NULL
added	NULL
for	NULL
18	NULL
h	NULL
;	NULL
cells	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
semiautomated	NULL
harvester	NULL
and	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
.	NULL

All	NULL
subsequent	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

Clones	NULL
were	NULL
judged	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
HSV	NULL
strains	NULL
or	NULL
purified	NULL
antigens	NULL
if	NULL
the	NULL
stimulation	NULL
index	NULL
(	NULL
cpm	NULL
of	NULL
[	NULL
*H	NULL
)	NULL
thymidine	NULL
incorporation	NULL
for	NULL
HSV	NULL
strain	NULL
or	NULL
antigen/cpm	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
for	NULL
mock	NULL
HDF	NULL
antigen	NULL
)	NULL
was	NULL
greater	NULL
than	NULL
4.0	NULL
.	NULL

Stimulation	NULL
indices	NULL
are	NULL
reported	NULL
with	NULL
two	NULL
significant	NULL
figures	NULL
to	NULL
reflect	NULL
the	NULL
precision	NULL
of	NULL
the	NULL
experimental	NULL
measurements	NULL
.	NULL

For	NULL
experiments	NULL
with	NULL
allogeneic	NULL
APC	NULL
,	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
both	NULL
mock	NULL
and	NULL
HSV	NULL
antigens	NULL
was	NULL
measured	NULL
with	NULL
allogeneic	NULL
irradiated	NULL
PBMC	NULL
,	NULL
and	NULL
stimulation	NULL
indices	NULL
were	NULL
calculated	NULL
from	NULL
these	NULL
two	NULL
measurements	NULL
.	NULL

Antibody	NULL
blocking	NULL
of	NULL
proliferation	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
(	NULL
MAbs	NULL
)	NULL
L243	NULL
(	NULL
38	NULL
)	NULL
,	NULL
B7/21	NULL
(	NULL
35	NULL
)	NULL
,	NULL
and	NULL
SPV-L3	NULL
(	NULL
39	NULL
)	NULL
recognize	NULL
HLA	NULL
DR	NULL
,	NULL
DP	NULL
,	NULL
and	NULL
DQ	NULL
framework	NULL
determinants	NULL
,	NULL
respectively	NULL
.	NULL

Supernatant	NULL
of	NULL
L243	NULL
cells	NULL
,	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
was	NULL
used	NULL
at	NULL
1:4	NULL
(	NULL
final	NULL
dilution	NULL
)	NULL
.	NULL

Purified	NULL
B7/21	NULL
,	NULL
obtained	NULL
from	NULL
Tom	NULL
Cotner	NULL
,	NULL
was	NULL
used	NULL
at	NULL
1:400	NULL
(	NULL
final	NULL
dilution	NULL
)	NULL
.	NULL

Purified	NULL
SPV-L3	NULL
,	NULL
obtained	NULL
from	NULL
Hans	NULL
Yssel	NULL
,	NULL
was	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

These	NULL
concentrations	NULL
were	NULL
determined	NULL
in	NULL
preliminary	NULL
titration	NULL
experiments	NULL
to	NULL
inhibit	NULL
proliferation	NULL
of	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
restricted	NULL
by	NULL
the	NULL
relevant	NULL
HLA	NULL
class	NULL
II	NULL
loci	NULL
by	NULL
greater	NULL
than	NULL
80	NULL
%	NULL
and	NULL
to	NULL
inhibit	NULL
proliferation	NULL
of	NULL
T-cell	NULL
clones	NULL
restricted	NULL
at	NULL
irrelevant	NULL
HLA	NULL
class	NULL
II	NULL
loci	NULL
by	NULL
less	NULL
than	NULL
15	NULL
%	NULL
.	NULL

Antigens	NULL
.	NULL

Antigens	NULL
were	NULL
prepared	NULL
from	NULL
viral	NULL
stocks	NULL
by	NULL
exposure	NULL
to	NULL
UV	NULL
light	NULL
for	NULL
30	NULL
min	NULL
at	NULL
10	NULL
cm	NULL
from	NULL
a	NULL
new	NULL
GTO38	NULL
bulb	NULL
,	NULL
eliminating	NULL
infectious	NULL
virus	NULL
.	NULL

Antigens	NULL
were	NULL
routinely	NULL
used	NULL
in	NULL
lymphoproliferation	NULL
assays	NULL
at	NULL
1:100	NULL
(	NULL
final	NULL
dilution	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
10°	NULL
to	NULL
10	NULL
'	NULL
PFU/ml	NULL
prior	NULL
to	NULL
UV	NULL
treatment	NULL
.	NULL

Recombinant	NULL
gB	NULL
and	NULL
gD	NULL
of	NULL
HSV-2	NULL
were	NULL
purified	NULL
from	NULL
trans-fected	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
(	NULL
8	NULL
)	NULL
.	NULL

gB2	NULL
is	NULL
truncated	NULL
at	NULL
amino	NULL
acid	NULL
696	NULL
,	NULL
and	NULL
gD2	NULL
is	NULL
truncated	NULL
at	NULL
amino	NULL
acid	NULL
302	NULL
.	NULL

Recombinant	NULL
glycoproteins	NULL
were	NULL
used	NULL
at	NULL
2	NULL
pg/ml	NULL
(	NULL
final	NULL
con-centration	NULL
)	NULL
(	NULL
52	NULL
)	NULL
.	NULL

gC	NULL
of	NULL
HSV-2	NULL
was	NULL
obtained	NULL
by	NULL
affinity	NULL
chromatography	NULL
of	NULL
infected	NULL
cells	NULL
(	NULL
43	NULL
)	NULL
and	NULL
used	NULL
at	NULL
2	NULL
pg/ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

Fusion	NULL
proteins	NULL
containing	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
the	NULL
yeast	NULL
protein	NULL
GALA	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
147	NULL
)	NULL
and	NULL
the	NULL
activation	NULL
domains	NULL
of	NULL
VP16	NULL
(	NULL
amino	NULL
acids	NULL
413	NULL
to	NULL
490	NULL
or	NULL
402	NULL
to	NULL
490	NULL
for	NULL
HSV-1	NULL
[	NULL
36	NULL
]	NULL
)	NULL
and	NULL
HSV-2	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
purified	NULL
from	NULL
Escherichia	NULL
coli	NULL
to	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
homogeneity	NULL
by	NULL
selective	NULL
precipitation	NULL
and	NULL
ion-exchange	NULL
chromatography	NULL
(	NULL
37a	NULL
)	NULL
.	NULL

Peptides	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
400	NULL
to	NULL
490	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
,	NULL
15	NULL
amino	NULL
acids	NULL
long	NULL
and	NULL
overlapping	NULL
by	NULL
10	NULL
amino	NULL
acids	NULL
(	NULL
Chiron	NULL
Mimotopes	NULL
,	NULL
Clayton	NULL
,	NULL
Australia	NULL
)	NULL
,	NULL
were	NULL
dissolved	NULL
in	NULL
20	NULL
%	NULL
acetonitrile-0.1	NULL
M	NULL
acetic	NULL
acid	NULL
at	NULL
2.0	NULL
mg/ml	NULL
and	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

Cytotoxicity	NULL
assays	NULL
.	NULL

Target	NULL
LCL	NULL
were	NULL
infected	NULL
for	NULL
18	NULL
h	NULL
with	NULL
HSV	NULL
or	NULL
vaccinia	NULL
viruses	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
5	NULL
,	NULL
loaded	NULL
with	NULL
°'Cr	NULL
,	NULL
and	NULL
washed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Cloned	NULL
lymphocytes	NULL
were	NULL
plated	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
RPMI-FC	NULL
in	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
,	NULL
and	NULL
targets	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
per	NULL
well	NULL
)	NULL
added	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
RPMI-FC	NULL
.	NULL

After	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
centrifuged	NULL
at	NULL
50	NULL
x	NULL
g	NULL
for	NULL
2	NULL
min	NULL
,	NULL
and	NULL
100	NULL
pl	NULL
of	NULL
supernatant	NULL
was	NULL
counted	NULL
with	NULL
a	NULL
gamma	NULL
counter	NULL
.	NULL

Allogeneic	NULL
target	NULL
cells	NULL
were	NULL
mismatched	NULL
at	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
loci	NULL
.	NULL

Results	NULL
are	NULL
reported	NULL
as	NULL
percent	NULL
specific	NULL
release	NULL
,	NULL
determined	NULL
as	NULL
[	NULL
(	NULL
mean	NULL
experimental	NULL
cpm	NULL
-	NULL
mean	NULL
spontaneous	NULL
cpm	NULL
)	NULL
/	NULL
(	NULL
mean	NULL
maximal	NULL
cpm	NULL
-	NULL
mean	NULL
spontaneous	NULL
cpm	NULL
)	NULL
]	NULL
X	NULL
100	NULL
.	NULL

Spontaneous	NULL
release	NULL
was	NULL
always	NULL
less	NULL
than	NULL
20	NULL
%	NULL
of	NULL
total	NULL
release	NULL
.	NULL

Vor	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
TABLE	NULL
1	NULL
.	NULL

HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
derived	NULL
directly	NULL
from	NULL
HSV-2	NULL
lesions	NULL
and	NULL
available	NULL
for	NULL
antigenic	NULL
specificity	NULL
analysis	NULL
No	NULL
.	NULL

of	NULL
HSV-specific	NULL
CD4*	NULL
clones	NULL
Patient	NULL
,	NULL
Serology	NULL
available	NULL
for	NULL
detailed	NULL
study	NULL
lesion	NULL
HSV-1	NULL
HsSVv-2	NULL
Type	NULL
Type	NULL
,	NULL
specific	NULL
``	NULL
common	NULL
1	NULL
,	NULL
A	NULL
+	NULL
+	NULL
6	NULL
1	NULL
1	NULL
,	NULL
B	NULL
+	NULL
+	NULL
1	NULL
2	NULL
2	NULL
-	NULL
+	NULL
2	NULL
1	NULL
3	NULL
,	NULL
B	NULL
+	NULL
+	NULL
2	NULL
10	NULL
4	NULL
-	NULL
+	NULL
8	NULL
4	NULL
5	NULL
-	NULL
+	NULL
7	NULL
3	NULL
``	NULL
Stimulation	NULL
index	NULL
for	NULL
HSV-2	NULL
antigen	NULL
greater	NULL
than	NULL
4.0	NULL
.	NULL

*	NULL
Stimulation	NULL
indices	NULL
for	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
antigens	NULL
greater	NULL
than	NULL
4.0	NULL
.	NULL

©	NULL
Includes	NULL
five	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
derived	NULL
from	NULL
bulk	NULL
culture	NULL
of	NULL
lesion-derived	NULL
T	NULL
lymphocytes	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

T-cell	NULL
clones	NULL
were	NULL
characterized	NULL
for	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
CD3	NULL
,	NULL
CD4	NULL
,	NULL
and	NULL
CD8	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Serology	NULL
.	NULL

Type-specific	NULL
serologies	NULL
for	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
were	NULL
performed	NULL
by	NULL
immunoblotting	NULL
(	NULL
2	NULL
)	NULL
.	NULL

RESULTS	NULL
Cloning	NULL
of	NULL
lesion	NULL
CD4*	NULL
HSV-specific	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
antigenic	NULL
specificities	NULL
of	NULL
47	NULL
lesion-derived	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
from	NULL
five	NULL
patients	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
representing	NULL
all	NULL
of	NULL
the	NULL
HSV-specific	NULL
clones	NULL
available	NULL
in	NULL
sufficient	NULL
number	NULL
for	NULL
detailed	NULL
study	NULL
.	NULL

A	NULL
total	NULL
of	NULL
42	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
obtained	NULL
directly	NULL
from	NULL
swabs	NULL
or	NULL
biopsies	NULL
of	NULL
recurrent	NULL
HSV-2	NULL
buttock	NULL
or	NULL
thigh	NULL
lesions	NULL
were	NULL
available	NULL
in	NULL
sufficient	NULL
number	NULL
for	NULL
detailed	NULL
studies	NULL
.	NULL

Details	NULL
of	NULL
the	NULL
cloning	NULL
procedure	NULL
and	NULL
reactivity	NULL
with	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
antigens	NULL
have	NULL
been	NULL
previously	NULL
reported	NULL
for	NULL
patient	NULL
1	NULL
,	NULL
lesion	NULL
A	NULL
,	NULL
and	NULL
patients	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
five	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
,	NULL
designated	NULL
1A¥.Bx	NULL
,	NULL
were	NULL
obtained	NULL
by	NULL
cloning	NULL
bulk	NULL
lesion-derived	NULL
cells	NULL
from	NULL
patient	NULL
1	NULL
,	NULL
lesion	NULL
A	NULL
,	NULL
after	NULL
19	NULL
days	NULL
of	NULL
bulk	NULL
culture	NULL
.	NULL

All	NULL
clones	NULL
were	NULL
CD3	NULL
#	NULL
,	NULL
CD4*	NULL
,	NULL
and	NULL
CD8~	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Overall	NULL
,	NULL
26	NULL
of	NULL
47	NULL
(	NULL
55	NULL
%	NULL
)	NULL
of	NULL
the	NULL
lesion-derived	NULL
HSV-specific	NULL
T-cell	NULL
clones	NULL
recognized	NULL
HSV-2	NULL
type-specific	NULL
epitopes	NULL
.	NULL

gB-	NULL
and	NULL
gD-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
.	NULL

The	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
were	NULL
each	NULL
tested	NULL
for	NULL
reactivity	NULL
with	NULL
recombinant	NULL
truncated	NULL
gB	NULL
and	NULL
gD	NULL
of	NULL
HSV-2	NULL
.	NULL

Three	NULL
clones	NULL
from	NULL
three	NULL
different	NULL
patients	NULL
had	NULL
stimulation	NULL
indices	NULL
of	NULL
greater	NULL
than	NULL
5.0	NULL
with	NULL
gB2	NULL
(	NULL
3B.268	NULL
,	NULL
4.4D3	NULL
,	NULL
and	NULL
5.5	NULL
)	NULL
,	NULL
and	NULL
one	NULL
clone	NULL
had	NULL
a	NULL
stimulation	NULL
index	NULL
of	NULL
greater	NULL
than	NULL
5.0	NULL
with	NULL
gD2	NULL
(	NULL
3B.134	NULL
)	NULL
(	NULL
Table	NULL
2	NULL
,	NULL
experiment	NULL
1	NULL
)	NULL
.	NULL

Proliferation	NULL
of	NULL
clone	NULL
3B.134	NULL
was	NULL
inhibited	NULL
by	NULL
HUMAN	NULL
LESIONAL	NULL
HSV-SPECIFIC	NULL
CD4*	NULL
T	NULL
CELLS	NULL
2805	NULL
50	NULL
aL	NULL
Auto	NULL
HSV-2	NULL
ze	NULL
40	NULL
ark	NULL
+	NULL
a	NULL
sersreres	NULL
e	NULL
I	NULL
Auto	NULL
vacgD2	NULL
®	NULL
30	NULL
@	NULL
m	NULL
w	NULL
o	NULL
m	NULL
a	NULL
o	NULL
me	NULL
@	NULL
@	NULL
Auto	NULL
vacWT	NULL
®	NULL
20	NULL
@	NULL
ane	NULL
t	NULL
6	NULL
moa	NULL
c+	NULL
m	NULL
>	NULL
@	NULL
[	NULL
ret	NULL
6	NULL
Allo	NULL
Mock	NULL
€	NULL
10	NULL
a	NULL
®	NULL
Allo	NULL
HSV-2	NULL
a	NULL
-	NULL
0	NULL
Adt	NULL
Auto	NULL
Mock	NULL
=	NULL
@	NULL
10:1	NULL
2.5:1	NULL
0.6:1	NULL
Effector	NULL
to	NULL
Target	NULL
Ratio	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Cytotoxic	NULL
activity	NULL
of	NULL
lesion	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
3B.134	NULL
against	NULL
HSV-2-	NULL
and	NULL
vaccinia	NULL
virus-infected	NULL
and	NULL
uninfected	NULL
autologous	NULL
(	NULL
Auto	NULL
)	NULL
and	NULL
allogeneic	NULL
(	NULL
Allo	NULL
)	NULL
LCL	NULL
.	NULL

Allogeneic	NULL
LCL	NULL
were	NULL
mismatched	NULL
at	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
loci	NULL
.	NULL

greater	NULL
than	NULL
90	NULL
%	NULL
by	NULL
anti-HLA	NULL
DP	NULL
MAb	NULL
but	NULL
not	NULL
by	NULL
anti-HLA	NULL
DR	NULL
MAb	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
gD2-specific	NULL
clone	NULL
3B.134	NULL
also	NULL
lysed	NULL
vaccinia	NULL
virus-gD2-	NULL
and	NULL
HSV-2-infected	NULL
autologous	NULL
target	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
uninfected	NULL
or	NULL
wild-type	NULL
vaccinia	NULL
virus-infected	NULL
autologous	NULL
cells	NULL
or	NULL
HSV-2-infected	NULL
allogeneic	NULL
cells	NULL
,	NULL
in	NULL
a	NULL
cytotoxicity	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
gB2-specific	NULL
clones	NULL
did	NULL
not	NULL
have	NULL
cytolytic	NULL
activity	NULL
against	NULL
HSV-2-	NULL
or	NULL
vaccinia	NULL
virus-gB2-infected	NULL
target	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
four	NULL
clones	NULL
reactive	NULL
with	NULL
gB2	NULL
or	NULL
gD2	NULL
recognized	NULL
type-common	NULL
determinants	NULL
(	NULL
Table	NULL
2	NULL
,	NULL
experiment	NULL
2	NULL
)	NULL
.	NULL

Subclones	NULL
of	NULL
each	NULL
of	NULL
the	NULL
gB-	NULL
and	NULL
gD-reactive	NULL
clones	NULL
obtained	NULL
at	NULL
one	NULL
cell	NULL
per	NULL
well	NULL
retained	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
reactivity	NULL
with	NULL
purified	NULL
recombinant	NULL
glycopro-teins	NULL
,	NULL
HSV-1	NULL
antigens	NULL
,	NULL
and	NULL
HSV-2	NULL
antigens	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
remaining	NULL
T-cell	NULL
clones	NULL
all	NULL
had	NULL
stimulation	NULL
indices	NULL
with	NULL
gB2	NULL
and	NULL
gD2	NULL
of	NULL
less	NULL
than	NULL
3.0	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Epitope	NULL
mapping	NULL
using	NULL
IRV	NULL
.	NULL

Fourteen	NULL
of	NULL
the	NULL
26	NULL
(	NULL
54	NULL
%	NULL
)	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
displayed	NULL
stimulation	NULL
indices	NULL
of	NULL
greater	NULL
than	NULL
4.0	NULL
to	NULL
at	NULL
least	NULL
one	NULL
viral	NULL
antigen	NULL
prepared	NULL
from	NULL
a	NULL
panel	NULL
of	NULL
IRV	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Twelve	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clones	NULL
did	NULL
not	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
antigen	NULL
prepared	NULL
from	NULL
any	NULL
of	NULL
the	NULL
IRV	NULL
.	NULL

Clone	NULL
4.3C12	NULL
is	NULL
shown	NULL
as	NULL
an	NULL
example	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

All	NULL
IRV	NULL
elicited	NULL
specific	NULL
proliferative	NULL
responses	NULL
from	NULL
bulk	NULL
PBMC	NULL
of	NULL
HSV-seropositive	NULL
individuals	NULL
,	NULL
demonstrating	NULL
their	NULL
antigenicity	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
T-cell	NULL
clones	NULL
reactive	NULL
with	NULL
type-common	NULL
epitopes	NULL
reacted	NULL
with	NULL
all	NULL
IRV	NULL
.	NULL

Clone	NULL
1A.2	NULL
is	NULL
shown	NULL
as	NULL
an	NULL
example	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Data	NULL
for	NULL
the	NULL
20	NULL
additional	NULL
type-common	NULL
and	NULL
11	NULL
additional	NULL
unmappable	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clones	NULL
are	NULL
not	NULL
included	NULL
in	NULL
Table	NULL
3	NULL
.	NULL

The	NULL
T-cell	NULL
clones	NULL
all	NULL
displayed	NULL
identical	NULL
patterns	NULL
of	NULL
reactivity	NULL
in	NULL
at	NULL
least	NULL
two	NULL
assays	NULL
.	NULL

Type-specific	NULL
T-cell	NULL
clones	NULL
recognized	NULL
diverse	NULL
HSV-2	NULL
antigens	NULL
.	NULL

Three	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
(	NULL
1A.1	NULL
,	NULL
1B.9F8	NULL
,	NULL
and	NULL
5.4	NULL
)	NULL
TABLE	NULL
2	NULL
.	NULL

Lesion-derived	NULL
CD4*	NULL
clones	NULL
specific	NULL
for	NULL
gB2	NULL
and	NULL
gD2	NULL
Mean	NULL
[	NULL
°H	NULL
]	NULL
incorporation	NULL
(	NULL
SD	NULL
)	NULL
``	NULL
Expt	NULL
Antigen	NULL
3B.134	NULL
3B.268	NULL
4.4D3	NULL
5.5	NULL
1	NULL
Mock	NULL
344	NULL
(	NULL
40	NULL
)	NULL
448	NULL
(	NULL
112	NULL
)	NULL
839	NULL
(	NULL
173	NULL
)	NULL
107	NULL
(	NULL
26	NULL
)	NULL
HSV-2	NULL
6,173	NULL
(	NULL
597	NULL
)	NULL
24,749	NULL
(	NULL
6,634	NULL
)	NULL
24,195	NULL
(	NULL
2,732	NULL
)	NULL
19,954	NULL
(	NULL
1,553	NULL
)	NULL
gB2	NULL
``	NULL
274	NULL
(	NULL
40	NULL
)	NULL
24,595	NULL
(	NULL
5,855	NULL
)	NULL
61,062	NULL
(	NULL
2,842	NULL
)	NULL
35,545	NULL
(	NULL
3,942	NULL
)	NULL
gD2	NULL
``	NULL
5,454	NULL
(	NULL
1,355	NULL
)	NULL
726	NULL
(	NULL
133	NULL
)	NULL
715	NULL
(	NULL
88	NULL
)	NULL
678	NULL
(	NULL
573	NULL
)	NULL
2	NULL
Mock	NULL
492	NULL
(	NULL
105	NULL
)	NULL
914	NULL
(	NULL
145	NULL
)	NULL
308	NULL
(	NULL
80	NULL
)	NULL
499	NULL
(	NULL
188	NULL
)	NULL
HSV-1	NULL
21,292	NULL
(	NULL
2,911	NULL
)	NULL
49,963	NULL
(	NULL
2,670	NULL
)	NULL
15,982	NULL
(	NULL
117	NULL
)	NULL
39,947	NULL
(	NULL
1,554	NULL
)	NULL
HSV-2	NULL
44,290	NULL
(	NULL
9,670	NULL
)	NULL
72,997	NULL
(	NULL
7,555	NULL
)	NULL
19,456	NULL
(	NULL
402	NULL
)	NULL
36,867	NULL
(	NULL
1,083	NULL
)	NULL
``	NULL
Determined	NULL
from	NULL
triplicate	NULL
samples	NULL
.	NULL

Glycoprotein-specific	NULL
reactivity	NULL
is	NULL
indicated	NULL
in	NULL
boldface	NULL
.	NULL

``	NULL
Used	NULL
at	NULL
2	NULL
ug/ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

2806	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

TABLE	NULL
3	NULL
.	NULL

Proliferative	NULL
responses	NULL
of	NULL
lesion-derived	NULL
,	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
to	NULL
antigens	NULL
prepared	NULL
from	NULL
HSV-1	NULL
,	NULL
HSV-2	NULL
,	NULL
and	NULL
HSV-1	NULL
x	NULL
HSV-2	NULL
IRV	NULL
Stimulation	NULL
index	NULL
``	NULL
Responder	NULL
HSV-1	NULL
HSV-2	NULL
RH1G7	NULL
RS1G25	NULL
RS1G31	NULL
R7015	NULL
(	NULL
0	NULL
``	NULL
)	NULL
(	NULL
0.0-1.0	NULL
)	NULL
(	NULL
0.30-0.46	NULL
)	NULL
(	NULL
0.59-0.73	NULL
)	NULL
(	NULL
0.67-0.73	NULL
)	NULL
(	NULL
0.82-1.0	NULL
)	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
1A.1	NULL
1.0	NULL
4.9	NULL
13	NULL
1.8	NULL
ND	NULL
0.9	NULL
1A.B.25	NULL
0.9	NULL
79	NULL
0.9	NULL
98	NULL
149	NULL
1.0	NULL
1B.9F8	NULL
1.3	NULL
18	NULL
20	NULL
0.6	NULL
1.2	NULL
1.2	NULL
2.1	NULL
1.3	NULL
10	NULL
1.5	NULL
22	NULL
1.5	NULL
1.4	NULL
2.3	NULL
0.8	NULL
21	NULL
1.5	NULL
56	NULL
57	NULL
1.0	NULL
3B.230	NULL
1.3	NULL
8.5	NULL
2.0	NULL
7.17	NULL
1.8	NULL
0.9	NULL
3B.294	NULL
1.4	NULL
23	NULL
1.4	NULL
26	NULL
24	NULL
1.5	NULL
4.1A11	NULL
2.0	NULL
12	NULL
1.8	NULL
13	NULL
13	NULL
1.4	NULL
4.2E1	NULL
1.7	NULL
15	NULL
1.1	NULL
14	NULL
11	NULL
1.4	NULL
4.2F10	NULL
0.6	NULL
81	NULL
2.6	NULL
68	NULL
103	NULL
3.4	NULL
4.3C3	NULL
0.9	NULL
5.2	NULL
0.5	NULL
6.4	NULL
6.8	NULL
1.0	NULL
5.1	NULL
1.1	NULL
13	NULL
1.7	NULL
16	NULL
11	NULL
1.7	NULL
5.4	NULL
1.0	NULL
27	NULL
25	NULL
1.1	NULL
2.9	NULL
2.8	NULL
5.19	NULL
1.5	NULL
6.0	NULL
1.2	NULL
1.2	NULL
1.8	NULL
6.6	NULL
Controls	NULL
PBMC	NULL
11	NULL
21	NULL
15	NULL
17	NULL
13	NULL
11	NULL
1A.2	NULL
``	NULL
25	NULL
15	NULL
20	NULL
29	NULL
24	NULL
28	NULL
4,3C12°	NULL
1.0	NULL
39	NULL
0.5	NULL
1.1	NULL
0.6	NULL
0.8	NULL
``	NULL
Data	NULL
defining	NULL
specificity	NULL
for	NULL
an	NULL
HSV-2	NULL
map	NULL
region	NULL
are	NULL
indicated	NULL
here	NULL
and	NULL
in	NULL
Tables	NULL
4	NULL
and	NULL
5	NULL
in	NULL
boldface	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

*	NULL
Approximate	NULL
HSV-2	NULL
map	NULL
region	NULL
.	NULL

©	NULL
Bulk	NULL
nonirradiated	NULL
PBMC	NULL
(	NULL
10°	NULL
)	NULL
from	NULL
an	NULL
HSV-1-	NULL
and	NULL
HSV-2-seropositive	NULL
donor	NULL
were	NULL
cultured	NULL
with	NULL
viral	NULL
antigen	NULL
at	NULL
1:100	NULL
(	NULL
final	NULL
dilution	NULL
)	NULL
and	NULL
labeled	NULL
with	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
from	NULL
days	NULL
5	NULL
to	NULL
6	NULL
.	NULL

``	NULL
Representative	NULL
clone	NULL
recognizing	NULL
a	NULL
type-common	NULL
epitope	NULL
.	NULL

Data	NULL
for	NULL
remaining	NULL
type-common	NULL
clones	NULL
are	NULL
not	NULL
shown	NULL
but	NULL
are	NULL
similar	NULL
.	NULL

©	NULL
Representative	NULL
clone	NULL
recognizing	NULL
an	NULL
HSV-2	NULL
type-specific	NULL
epitope	NULL
not	NULL
included	NULL
in	NULL
the	NULL
panel	NULL
of	NULL
IRV	NULL
.	NULL

Data	NULL
for	NULL
additional	NULL
clones	NULL
unreactive	NULL
with	NULL
the	NULL
panel	NULL
of	NULL
IRV	NULL
are	NULL
not	NULL
shown	NULL
but	NULL
are	NULL
similar	NULL
.	NULL

reacted	NULL
with	NULL
IRV	NULL
RH1G7	NULL
(	NULL
10	NULL
,	NULL
32	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
approximately	NULL
0.30	NULL
to	NULL
0.46	NULL
map	NULL
units	NULL
within	NULL
the	NULL
HSV-2	NULL
genome	NULL
.	NULL

Clones	NULL
1A¥.1	NULL
and	NULL
1B.9F8	NULL
were	NULL
recovered	NULL
from	NULL
lesions	NULL
from	NULL
the	NULL
same	NULL
patient	NULL
on	NULL
opposite	NULL
buttocks	NULL
separated	NULL
in	NULL
time	NULL
by	NULL
1	NULL
year	NULL
.	NULL

One	NULL
HSV-2	NULL
type-specific	NULL
clone	NULL
(	NULL
5.19	NULL
)	NULL
reactive	NULL
with	NULL
IRV	NULL
R7015	NULL
(	NULL
32	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
approximately	NULL
0.82	NULL
to	NULL
1.0	NULL
map	NULL
units	NULL
within	NULL
the	NULL
HSV-2	NULL
genome	NULL
,	NULL
was	NULL
isolated	NULL
from	NULL
patient	NULL
5	NULL
.	NULL

A	NULL
total	NULL
of	NULL
10	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
reacted	NULL
with	NULL
IRV	NULL
RS1G25	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
approximately	NULL
0.59	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
within	NULL
the	NULL
HSV-2	NULL
genome	NULL
.	NULL

Of	NULL
these	NULL
10	NULL
clones	NULL
,	NULL
8	NULL
(	NULL
1A¥.B.25	NULL
,	NULL
2.3	NULL
,	NULL
3B.294	NULL
,	NULL
4.1A11	NULL
,	NULL
4.2E1	NULL
,	NULL
4.2F10	NULL
,	NULL
4.3C3	NULL
,	NULL
and	NULL
5.1	NULL
)	NULL
also	NULL
reacted	NULL
with	NULL
IRV	NULL
RS1G31	NULL
(	NULL
31	NULL
)	NULL
,	NULL
indicating	NULL
specificity	NULL
for	NULL
an	NULL
epitope	NULL
encoded	NULL
by	NULL
HSV-2	NULL
between	NULL
approximately	NULL
0.67	NULL
and	NULL
0.73	NULL
map	NULL
units	NULL
.	NULL

All	NULL
eight	NULL
clones	NULL
reactive	NULL
with	NULL
RS1G31	NULL
were	NULL
also	NULL
reactive	NULL
with	NULL
RS1G25	NULL
.	NULL

Two	NULL
clones	NULL
(	NULL
2.1	NULL
and	NULL
3B.230	NULL
)	NULL
reacted	NULL
with	NULL
antigen	NULL
prepared	NULL
from	NULL
RS1G25	NULL
but	NULL
not	NULL
RS1G31	NULL
,	NULL
indicating	NULL
specificity	NULL
for	NULL
an	NULL
antigen	NULL
encoded	NULL
by	NULL
HSV-2	NULL
between	NULL
approximately	NULL
0.59	NULL
and	NULL
0.67	NULL
map	NULL
units	NULL
.	NULL

gC-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
.	NULL

As	NULL
the	NULL
gene	NULL
for	NULL
gC2	NULL
is	NULL
located	NULL
at	NULL
approximately	NULL
0.64	NULL
map	NULL
units	NULL
(	NULL
41	NULL
)	NULL
,	NULL
the	NULL
two	NULL
clones	NULL
reactive	NULL
with	NULL
RS1G25	NULL
but	NULL
not	NULL
RS1G31	NULL
(	NULL
2.1	NULL
and	NULL
3B.230	NULL
)	NULL
were	NULL
evaluated	NULL
for	NULL
proliferative	NULL
responses	NULL
to	NULL
affinity-purified	NULL
gC2	NULL
and	NULL
special	NULL
HSV	NULL
strains	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

Clone	NULL
3B.230	NULL
had	NULL
a	NULL
specific	NULL
proliferative	NULL
response	NULL
to	NULL
gC2	NULL
.	NULL

This	NULL
clone	NULL
also	NULL
proliferated	NULL
in	NULL
response	NULL
to	NULL
the	NULL
recombinant	NULL
HSV-1	NULL
strain	NULL
MP801-1	NULL
,	NULL
expressing	NULL
the	NULL
HSV-2	NULL
gC	NULL
gene	NULL
,	NULL
and	NULL
failed	NULL
to	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
the	NULL
HSV-2	NULL
strain	NULL
GpS1	NULL
,	NULL
which	NULL
does	NULL
not	NULL
express	NULL
gC2	NULL
.	NULL

Subclones	NULL
of	NULL
3B.230	NULL
obtained	NULL
at	NULL
one	NULL
cell	NULL
per	NULL
well	NULL
displayed	NULL
an	NULL
identical	NULL
pattern	NULL
of	NULL
reactivity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Clone	NULL
3B.230	NULL
was	NULL
also	NULL
reactive	NULL
in	NULL
cytotoxicity	NULL
assays	NULL
with	NULL
RS1G25	NULL
and	NULL
MP801-1	NULL
but	NULL
not	NULL
RS1G31	NULL
or	NULL
GpS1	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
reactivity	NULL
obtained	NULL
in	NULL
proliferation	NULL
assays	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
clone	NULL
2.1	NULL
did	NULL
not	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
MP8O01-1	NULL
or	NULL
purified	NULL
gC2	NULL
and	NULL
did	NULL
react	NULL
with	NULL
the	NULL
GpS1	NULL
,	NULL
indicating	NULL
reactivity	NULL
with	NULL
a	NULL
HSV-2	NULL
type-specific	NULL
epitope	NULL
not	NULL
contained	NULL
within	NULL
gC2	NULL
.	NULL

CD4*	NULL
T-cell	NULL
clones	NULL
with	NULL
specificity	NULL
for	NULL
VP16	NULL
and	NULL
other	NULL
antigens	NULL
mapping	NULL
to	NULL
RS1IG31	NULL
.	NULL

Eight	NULL
lesion-derived	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
,	NULL
including	NULL
at	NULL
least	NULL
one	NULL
from	NULL
each	NULL
patient	NULL
,	NULL
reacted	NULL
with	NULL
an	NULL
HSV-2	NULL
epitope	NULL
contained	NULL
within	NULL
IRV	NULL
RS1G31	NULL
and	NULL
thus	NULL
mapping	NULL
to	NULL
approximately	NULL
0.67	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

One	NULL
of	NULL
these	NULL
,	NULL
clone	NULL
1A¥.B.25.1	NULL
,	NULL
proliferated	NULL
in	NULL
response	NULL
to	NULL
the	NULL
IRV	NULL
RP-2	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
only	NULL
the	NULL
HSV-2	NULL
gene	NULL
TABLE	NULL
4	NULL
.	NULL

Proliferative	NULL
response	NULL
of	NULL
lesion-derived	NULL
CD4*	NULL
clones	NULL
2.1	NULL
and	NULL
3B.230	NULL
to	NULL
purified	NULL
gC2	NULL
and	NULL
antigens	NULL
prepared	NULL
from	NULL
various	NULL
HSV	NULL
strains	NULL
Stimulation	NULL
index	NULL
Clone	NULL
HSV-1	NULL
HSV-2	NULL
RS1G25	NULL
RS1G31	NULL
MP801-1°	NULL
GpS1	NULL
``	NULL
gCZz	NULL
2.1	NULL
1.8	NULL
5.1	NULL
5.5	NULL
1.1	NULL
0.8	NULL
6.1	NULL
1.4	NULL
3B.230	NULL
0.8	NULL
23	NULL
22	NULL
1.4	NULL
35	NULL
1.0	NULL
48	NULL
``	NULL
HSV-1	NULL
strain	NULL
containing	NULL
the	NULL
gene	NULL
for	NULL
gC	NULL
of	NULL
HSV-2	NULL
.	NULL

``	NULL
HSV-2	NULL
strain	NULL
which	NULL
does	NULL
not	NULL
express	NULL
gC	NULL
.	NULL

©	NULL
Used	NULL
at	NULL
2	NULL
ug/ml	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

Vou	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
Auto	NULL
HSV-2	NULL
Auto	NULL
HSV-1	NULL
Auto	NULL
mock	NULL
Auto	NULL
R7015	NULL
Auto	NULL
RS1G25	NULL
Auto	NULL
RS1G31	NULL
Auto	NULL
R7015	NULL
Auto	NULL
GPSI1	NULL
Auto	NULL
MP8O1-1	NULL
Allo	NULL
HSV-2	NULL
Allo	NULL
mock	NULL
;	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
35	NULL
%	NULL
Specific	NULL
release	NULL
at	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
10:1	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Cytotoxic	NULL
activity	NULL
of	NULL
gC2-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
3B.230	NULL
against	NULL
infected	NULL
and	NULL
uninfected	NULL
autologous	NULL
(	NULL
Auto	NULL
)	NULL
and	NULL
allogeneic	NULL
(	NULL
Allo	NULL
)	NULL
LCL	NULL
.	NULL

HSV-1	NULL
x	NULL
HSV-2	NULL
IRV	NULL
RS1G25	NULL
contains	NULL
HSV-2	NULL
DNA	NULL
from	NULL
approximately	NULL
0.59	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
within	NULL
an	NULL
HSV-1	NULL
background	NULL
.	NULL

MP801-1	NULL
is	NULL
an	NULL
HSV-1	NULL
strain	NULL
containing	NULL
the	NULL
gene	NULL
for	NULL
gC	NULL
of	NULL
HSV-2	NULL
.	NULL

GpS1	NULL
is	NULL
an	NULL
HSV-2	NULL
strain	NULL
which	NULL
does	NULL
not	NULL
express	NULL
gC	NULL
.	NULL

Allogeneic	NULL
LCL	NULL
were	NULL
mismatched	NULL
at	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
loci	NULL
.	NULL

Data	NULL
are	NULL
percent	NULL
specific	NULL
release	NULL
at	NULL
an	NULL
effector-to-target	NULL
(	NULL
E	NULL
:	NULL
T	NULL
)	NULL
ratio	NULL
of	NULL
10:1.	NULL
for	NULL
VP16	NULL
within	NULL
an	NULL
HSV-1	NULL
background	NULL
.	NULL

Clone	NULL
1A.B.25.1	NULL
is	NULL
a	NULL
subclone	NULL
of	NULL
1A¥.B.25	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

Clones	NULL
2.3	NULL
,	NULL
3B.294	NULL
,	NULL
4.1A11	NULL
,	NULL
4.2E1	NULL
,	NULL
and	NULL
4.2F10	NULL
did	NULL
not	NULL
react	NULL
with	NULL
RP-2	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
.	NULL

Clones	NULL
4.3C3	NULL
and	NULL
5.5	NULL
were	NULL
not	NULL
available	NULL
for	NULL
evaluation	NULL
with	NULL
RP-2	NULL
antigen	NULL
.	NULL

Allogeneic	NULL
PBMC	NULL
from	NULL
patient	NULL
5	NULL
,	NULL
sharing	NULL
HLA	NULL
DR3	NULL
and	NULL
DQ2	NULL
with	NULL
patient	NULL
1	NULL
,	NULL
presented	NULL
HSV-2	NULL
antigen	NULL
to	NULL
clone	NULL
1A¥.B.25.1	NULL
(	NULL
Table	NULL
6	NULL
)	NULL
.	NULL

Alloreactivity	NULL
against	NULL
the	NULL
patient	NULL
5	NULL
PBMC	NULL
was	NULL
not	NULL
present	NULL
,	NULL
as	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
in	NULL
response	NULL
to	NULL
these	NULL
allogeneic	NULL
PBMC	NULL
and	NULL
mock	NULL
antigen	NULL
was	NULL
less	NULL
than	NULL
500	NULL
cpm	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Proliferation	NULL
of	NULL
clone	NULL
1¥.B.25.1	NULL
to	NULL
autologous	NULL
PBMC	NULL
and	NULL
HSV-2	NULL
antigen	NULL
was	NULL
inhibited	NULL
more	NULL
than	NULL
90	NULL
%	NULL
by	NULL
anti-HLA	NULL
DQ	NULL
MAb	NULL
SPV-L3	NULL
but	NULL
not	NULL
inhibited	NULL
by	NULL
anti-HLA	NULL
DR	NULL
or	NULL
anti-HLA	NULL
DP	NULL
MAbs	NULL
(	NULL
Table	NULL
6	NULL
)	NULL
,	NULL
identifying	NULL
the	NULL
restriction	NULL
element	NULL
as	NULL
DQ2	NULL
.	NULL

A	NULL
fusion	NULL
protein	NULL
bearing	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
VP16	NULL
of	NULL
HSV-1	NULL
or	NULL
HSV-2	NULL
linked	NULL
to	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
the	NULL
yeast	NULL
GALA	NULL
protein	NULL
was	NULL
purified	NULL
after	NULL
expression	NULL
in	NULL
E.	NULL
coli	NULL
.	NULL

Dose-dependent	NULL
proliferative	NULL
responses	NULL
were	NULL
observed	NULL
at	NULL
HSV-2	NULL
fusion	NULL
protein	NULL
concentrations	NULL
of	NULL
between	NULL
0.5	NULL
and	NULL
8	NULL
pg/ml	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

No	NULL
proliferation	NULL
was	NULL
elicited	NULL
by	NULL
the	NULL
HSV-1	NULL
fusion	NULL
protein	NULL
.	NULL

Peptides	NULL
containing	NULL
amino	NULL
acids	NULL
425	NULL
to	NULL
439	NULL
(	NULL
LRLDGEEVDMTPADA	NULL
)	NULL
and	NULL
430	NULL
to	NULL
444	NULL
(	NULL
EEVDMTPADALDDFD	NULL
)	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
(	NULL
11	NULL
)	NULL
both	NULL
induced	NULL
specific	NULL
proliferative	NULL
responses	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

TABLE	NULL
5	NULL
.	NULL

Proliferative	NULL
responses	NULL
of	NULL
type-specific	NULL
lesion-derived	NULL
CD4+*	NULL
clones	NULL
recognizing	NULL
an	NULL
HSV-2	NULL
antigen	NULL
mapping	NULL
to	NULL
RS1G31	NULL
(	NULL
approximately	NULL
0.67	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
)	NULL
to	NULL
RP-2	NULL
antigen	NULL
Stimulation	NULL
index	NULL
``	NULL
Clone	NULL
HSV-1	NULL
HSV-2	NULL
RS1G31	NULL
RP-2	NULL
1A.B.25.1	NULL
3.0	NULL
52	NULL
85	NULL
52	NULL
2.3	NULL
1.1	NULL
30	NULL
46	NULL
1.6	NULL
3B.294	NULL
1.8	NULL
21	NULL
37	NULL
3.2	NULL
4.1A11	NULL
0.9	NULL
21	NULL
28	NULL
2.1	NULL
4.2E1	NULL
1.3	NULL
26	NULL
29	NULL
2.7	NULL
4.2F10	NULL
3.5	NULL
69	NULL
77	NULL
4.6	NULL
``	NULL
Antigens	NULL
used	NULL
at	NULL
1:100	NULL
(	NULL
final	NULL
dilution	NULL
)	NULL
except	NULL
for	NULL
clones	NULL
4.1A11	NULL
and	NULL
4.2E1	NULL
(	NULL
1:30	NULL
[	NULL
final	NULL
dilution	NULL
]	NULL
)	NULL
.	NULL

HUMAN	NULL
LESIONAL	NULL
HSV-SPECIFIC	NULL
CD4*	NULL
T	NULL
CELLS	NULL
2807	NULL
TABLE	NULL
6	NULL
.	NULL

Lesion-derived	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
1¥.B.25	NULL
is	NULL
restricted	NULL
by	NULL
HLA	NULL
DQ2	NULL
APC	NULL
MAb	NULL
Stimulation	NULL
index	NULL
Autologous	NULL
None	NULL
22	NULL
Anti-DR	NULL
27	NULL
Anti-DP	NULL
27	NULL
Anti-DQ	NULL
1.5	NULL
Allogeneic	NULL
None	NULL
34	NULL
``	NULL
Autologous	NULL
PBMC	NULL
are	NULL
HLA	NULL
DR3,11	NULL
,	NULL
DQ2	NULL
,	NULL
7	NULL
;	NULL
allogeneic	NULL
PBMC	NULL
are	NULL
HLA	NULL
DR3	NULL
,	NULL
DQz	NULL
.	NULL

DISCUSSION	NULL
Limited	NULL
information	NULL
concerning	NULL
the	NULL
antigenic	NULL
specificity	NULL
of	NULL
human	NULL
HSV-specific	NULL
T	NULL
lymphocytes	NULL
is	NULL
available	NULL
.	NULL

Secondary	NULL
in	NULL
vitro	NULL
restimulation	NULL
of	NULL
PBMC	NULL
with	NULL
HSV	NULL
antigen	NULL
prior	NULL
to	NULL
cloning	NULL
has	NULL
previously	NULL
been	NULL
necessary	NULL
to	NULL
obtain	NULL
CD4*	NULL
HSV-specific	NULL
T-cell	NULL
clones	NULL
(	NULL
52	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
to	NULL
what	NULL
extent	NULL
the	NULL
antigenic	NULL
specificities	NULL
and	NULL
effector	NULL
functions	NULL
of	NULL
clones	NULL
obtained	NULL
with	NULL
this	NULL
method	NULL
reflect	NULL
the	NULL
properties	NULL
of	NULL
T	NULL
lymphocytes	NULL
that	NULL
have	NULL
migrated	NULL
to	NULL
,	NULL
and	NULL
been	NULL
activated	NULL
within	NULL
,	NULL
recurrent	NULL
HSV	NULL
lesions	NULL
.	NULL

CD4*	NULL
T-cell	NULL
clones	NULL
obtained	NULL
in	NULL
this	NULL
manner	NULL
have	NULL
been	NULL
primarily	NULL
specific	NULL
for	NULL
gB	NULL
and	NULL
gD	NULL
(	NULL
52	NULL
)	NULL
.	NULL

We	NULL
have	NULL
used	NULL
the	NULL
in	NULL
situ	NULL
enrichment	NULL
of	NULL
HSV-specific	NULL
T	NULL
cells	NULL
in	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
(	NULL
23	NULL
)	NULL
to	NULL
obtain	NULL
T	NULL
cells	NULL
for	NULL
cloning	NULL
without	NULL
the	NULL
requirement	NULL
for	NULL
in	NULL
vitro	NULL
restimulation	NULL
with	NULL
HSV	NULL
antigen	NULL
.	NULL

The	NULL
T-cell	NULL
cultures	NULL
used	NULL
in	NULL
this	NULL
study	NULL
were	NULL
believed	NULL
to	NULL
be	NULL
clonal	NULL
.	NULL

It	NULL
was	NULL
necessary	NULL
to	NULL
initially	NULL
plate	NULL
the	NULL
lesion	NULL
cells	NULL
at	NULL
greater	NULL
than	NULL
one	NULL
cell	NULL
per	NULL
well	NULL
because	NULL
of	NULL
the	NULL
low	NULL
purity	NULL
of	NULL
lymphocytes	NULL
(	NULL
<	NULL
1	NULL
%	NULL
)	NULL
in	NULL
the	NULL
lesion	NULL
cell	NULL
preparations	NULL
.	NULL

Since	NULL
the	NULL
maximum	NULL
percentage	NULL
of	NULL
wells	NULL
positive	NULL
for	NULL
growth	NULL
was	NULL
48.7	NULL
%	NULL
(	NULL
23	NULL
)	NULL
,	NULL
the	NULL
average	NULL
number	NULL
of	NULL
lymphocytes	NULL
plated	NULL
per	NULL
well	NULL
is	NULL
estimated	NULL
to	NULL
be	NULL
less	NULL
than	NULL
one	NULL
(	NULL
20	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Since	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
all	NULL
lesion-derived	NULL
T-cell	NULL
cultures	NULL
were	NULL
HSV	NULL
specific	NULL
(	NULL
23	NULL
)	NULL
,	NULL
it	NULL
is	NULL
very	NULL
unlikely	NULL
that	NULL
more	NULL
than	NULL
one	NULL
HSV-specific	NULL
T-cell	NULL
clone	NULL
would	NULL
be	NULL
represented	NULL
within	NULL
an	NULL
individual	NULL
culture	NULL
of	NULL
lesion	NULL
lymphocytes	NULL
.	NULL

All	NULL
of	NULL
the	NULL
cultures	NULL
tested	NULL
were	NULL
>	NULL
97	NULL
%	NULL
CD4*	NULL
and	NULL
<	NULL
3	NULL
%	NULL
CD8*	NULL
.	NULL

Multiple	NULL
subclones	NULL
were	NULL
evaluated	NULL
for	NULL
Antigen	NULL
Hgy-	NULL
F	NULL
Clone	NULL
1A.B.25.1	NULL
HSv-2	NULL
HSV-2	NULL
no	NULL
A	NULL
HSV-2	NULL
allo	NULL
A	NULL
VP16	NULL
(	NULL
1	NULL
)	NULL
413-490	NULL
8	NULL
ug/ml	NULL
vp16	NULL
(	NULL
2	NULL
)	NULL
402-490	NULL
8	NULL
353	NULL
1ugal	NULL
0.5	NULL
ug/ml	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Stimulation	NULL
Index	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Proliferative	NULL
responses	NULL
of	NULL
lesion	NULL
CD4*	NULL
clone	NULL
1A¥.B.25.1	NULL
to	NULL
HSV	NULL
antigens	NULL
,	NULL
purified	NULL
recombinant	NULL
GALA-VP16	NULL
fusion	NULL
proteins	NULL
containing	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
147	NULL
of	NULL
yeast	NULL
GAL4	NULL
linked	NULL
to	NULL
amino	NULL
acids	NULL
413	NULL
to	NULL
490	NULL
of	NULL
VP16	NULL
(	NULL
HSV-1	NULL
)	NULL
or	NULL
amino	NULL
acids	NULL
402	NULL
to	NULL
490	NULL
of	NULL
VP16	NULL
(	NULL
HSV-2	NULL
)	NULL
,	NULL
and	NULL
peptides	NULL
from	NULL
VP16	NULL
of	NULL
HSV-2	NULL
.	NULL

Allogeneic	NULL
(	NULL
allo	NULL
)	NULL
PBMC	NULL
were	NULL
mismatched	NULL
at	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
loci	NULL
.	NULL

2808	NULL
KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

clones	NULL
1A.B.25	NULL
,	NULL
2.3	NULL
,	NULL
3B.134	NULL
,	NULL
3B.230	NULL
,	NULL
3B.268	NULL
,	NULL
4.2E1	NULL
,	NULL
and	NULL
4.2F10	NULL
,	NULL
and	NULL
all	NULL
were	NULL
found	NULL
to	NULL
retain	NULL
specific	NULL
proliferative	NULL
responses	NULL
to	NULL
HSV-2	NULL
antigen	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
antigenic	NULL
specificity	NULL
of	NULL
subclones	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
IRV	NULL
mapping	NULL
or	NULL
reactivity	NULL
with	NULL
HSV	NULL
glycopro-teins	NULL
,	NULL
has	NULL
been	NULL
identical	NULL
with	NULL
that	NULL
of	NULL
the	NULL
parent	NULL
culture	NULL
in	NULL
all	NULL
of	NULL
12	NULL
clones	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
no	NULL
cases	NULL
of	NULL
reactivity	NULL
of	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clones	NULL
with	NULL
more	NULL
than	NULL
one	NULL
nonoverlapping	NULL
IRV	NULL
were	NULL
noted	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

The	NULL
lesion	NULL
CD4*	NULL
response	NULL
appears	NULL
to	NULL
be	NULL
directed	NULL
against	NULL
a	NULL
variety	NULL
of	NULL
viral	NULL
epitopes	NULL
.	NULL

Using	NULL
lesion-derived	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
from	NULL
five	NULL
individuals	NULL
,	NULL
we	NULL
identified	NULL
at	NULL
least	NULL
10	NULL
different	NULL
epitopes	NULL
:	NULL
1	NULL
to	NULL
3	NULL
,	NULL
epitopes	NULL
contained	NULL
within	NULL
gB	NULL
,	NULL
gC	NULL
,	NULL
and	NULL
gD	NULL
;	NULL
4	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
contained	NULL
within	NULL
amino	NULL
acids	NULL
425	NULL
to	NULL
444	NULL
of	NULL
VP16	NULL
;	NULL
5	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
or	NULL
epitopes	NULL
mapping	NULL
to	NULL
approximately	NULL
0.30	NULL
to	NULL
0.46	NULL
map	NULL
units	NULL
;	NULL
6	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
or	NULL
epitopes	NULL
mapping	NULL
to	NULL
approximately	NULL
0.59	NULL
to	NULL
0.67	NULL
map	NULL
units	NULL
but	NULL
not	NULL
gC	NULL
;	NULL
7	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
(	NULL
or	NULL
epitopes	NULL
)	NULL
mapping	NULL
to	NULL
approximately	NULL
0.67	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
but	NULL
not	NULL
VP16	NULL
;	NULL
8	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
(	NULL
or	NULL
epitopes	NULL
)	NULL
mapping	NULL
to	NULL
approximately	NULL
0.82	NULL
to	NULL
1.0	NULL
map	NULL
units	NULL
;	NULL
9	NULL
,	NULL
a	NULL
type-specific	NULL
HSV-2	NULL
epitope	NULL
(	NULL
or	NULL
epitopes	NULL
)	NULL
not	NULL
mappable	NULL
with	NULL
the	NULL
current	NULL
panel	NULL
of	NULL
IRV	NULL
;	NULL
and	NULL
10	NULL
,	NULL
a	NULL
type-common	NULL
epitope	NULL
(	NULL
or	NULL
epitopes	NULL
)	NULL
in	NULL
addition	NULL
to	NULL
those	NULL
present	NULL
in	NULL
recombinant	NULL
soluble	NULL
gB	NULL
and	NULL
gD	NULL
.	NULL

It	NULL
is	NULL
of	NULL
interest	NULL
that	NULL
each	NULL
of	NULL
the	NULL
five	NULL
patients	NULL
studied	NULL
yielded	NULL
at	NULL
least	NULL
one	NULL
lesion-derived	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
reactive	NULL
with	NULL
a	NULL
HSV-2	NULL
epitope	NULL
present	NULL
within	NULL
IRV	NULL
RS1G31	NULL
and	NULL
thus	NULL
mapping	NULL
to	NULL
the	NULL
approximate	NULL
region	NULL
of	NULL
0.67	NULL
to	NULL
0.73	NULL
map	NULL
units	NULL
.	NULL

The	NULL
maximum	NULL
left-hand	NULL
border	NULL
of	NULL
HSV-2	NULL
sequences	NULL
contained	NULL
within	NULL
IRV	NULL
RS1G31	NULL
is	NULL
defined	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
HSV-1	NULL
KpnI-A	NULL
to	NULL
-Y	NULL
``	NULL
cleavage	NULL
site	NULL
at	NULL
nucleotide	NULL
103101	NULL
(	NULL
31	NULL
)	NULL
,	NULL
within	NULL
the	NULL
HSV-1	NULL
UL47	NULL
coding	NULL
sequence	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
minimum	NULL
left-hand	NULL
border	NULL
of	NULL
HSV-2	NULL
sequences	NULL
in	NULL
RS1G31	NULL
has	NULL
been	NULL
mapped	NULL
in	NULL
the	NULL
present	NULL
experiments	NULL
to	NULL
be	NULL
within	NULL
or	NULL
5	NULL
'	NULL
of	NULL
the	NULL
DNA	NULL
encoding	NULL
amino	NULL
acids	NULL
425	NULL
to	NULL
444	NULL
of	NULL
VP16	NULL
(	NULL
UL48	NULL
)	NULL
of	NULL
HSV-2	NULL
.	NULL

The	NULL
minimum	NULL
right	NULL
border	NULL
of	NULL
the	NULL
HSV-2	NULL
sequences	NULL
within	NULL
RS1G31	NULL
is	NULL
defined	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
HSV-2	NULL
EcoRI-L	NULL
to	NULL
-H	NULL
cleavage	NULL
site	NULL
(	NULL
31	NULL
)	NULL
;	NULL
this	NULL
site	NULL
can	NULL
not	NULL
be	NULL
precisely	NULL
placed	NULL
with	NULL
published	NULL
sequence	NULL
information	NULL
.	NULL

The	NULL
maximal	NULL
right-hand	NULL
border	NULL
of	NULL
HSV-2	NULL
sequences	NULL
within	NULL
IRV	NULL
RS1G31	NULL
is	NULL
defined	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
HSV-2	NULL
Bg/II-I	NULL
to	NULL
-H	NULL
cleavage	NULL
site	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
crossover	NULL
point	NULL
must	NULL
lie	NULL
to	NULL
the	NULL
left	NULL
of	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
HSV-2	NULL
ULS3	NULL
gene	NULL
,	NULL
since	NULL
the	NULL
HSV	NULL
Bgi/lII-I	NULL
to	NULL
-H	NULL
cleavage	NULL
site	NULL
is	NULL
not	NULL
present	NULL
in	NULL
the	NULL
ULS3	NULL
coding	NULL
sequence	NULL
(	NULL
15	NULL
)	NULL
or	NULL
the	NULL
remaining	NULL
rightward	NULL
region	NULL
of	NULL
UL	NULL
of	NULL
HSV-2	NULL
(	NULL
25	NULL
,	NULL
34	NULL
)	NULL
.	NULL

IRV	NULL
RS1G31	NULL
may	NULL
,	NULL
therefore	NULL
,	NULL
contain	NULL
HSV-2	NULL
coding	NULL
sequences	NULL
for	NULL
some	NULL
of	NULL
ULA7	NULL
of	NULL
HSV-2	NULL
,	NULL
but	NULL
the	NULL
HSV-2	NULL
sequences	NULL
do	NULL
not	NULL
extend	NULL
into	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
ULS53	NULL
of	NULL
HSV-2	NULL
.	NULL

Of	NULL
the	NULL
total	NULL
of	NULL
eight	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
mapping	NULL
to	NULL
IRV	NULL
RS1G31	NULL
,	NULL
only	NULL
one	NULL
of	NULL
six	NULL
available	NULL
for	NULL
testing	NULL
reacted	NULL
with	NULL
IRV	NULL
RP-2	NULL
and	NULL
was	NULL
thus	NULL
specific	NULL
for	NULL
the	NULL
UL48	NULL
gene	NULL
product	NULL
VP16	NULL
.	NULL

The	NULL
0.67-0.73	NULL
region	NULL
of	NULL
the	NULL
HSV-2	NULL
genome	NULL
contains	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
VP16	NULL
,	NULL
the	NULL
genes	NULL
for	NULL
the	NULL
abundant	NULL
tegument	NULL
proteins	NULL
ULA47	NULL
and	NULL
UL49	NULL
and	NULL
the	NULL
genes	NULL
for	NULL
the	NULL
probable	NULL
membrane	NULL
glycoprotein	NULL
ULA9.5	NULL
or	NULL
ULAIA	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
16	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
UL50	NULL
and	NULL
ULS2	NULL
protein	NULL
products	NULL
are	NULL
perhaps	NULL
less	NULL
likely	NULL
candidates	NULL
for	NULL
CD4*	NULL
T-cell	NULL
antigens	NULL
,	NULL
since	NULL
they	NULL
are	NULL
present	NULL
in	NULL
small	NULL
amounts	NULL
in	NULL
infected	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
47	NULL
)	NULL
and	NULL
have	NULL
not	NULL
been	NULL
identified	NULL
in	NULL
virions	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
ULS1	NULL
gene	NULL
product	NULL
of	NULL
HSV	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Study	NULL
of	NULL
additional	NULL
HSV-2	NULL
lesions	NULL
and	NULL
finer	NULL
definition	NULL
of	NULL
the	NULL
T-cell	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
will	NULL
allow	NULL
exploration	NULL
of	NULL
the	NULL
possibility	NULL
that	NULL
an	NULL
immunodominant	NULL
HSV-2	NULL
type-specific	NULL
CD4*	NULL
antigen	NULL
may	NULL
be	NULL
encoded	NULL
by	NULL
a	NULL
gene	NULL
in	NULL
this	NULL
portion	NULL
of	NULL
the	NULL
genome	NULL
.	NULL

The	NULL
lesion-derived	NULL
clone	NULL
1A.B.25	NULL
is	NULL
the	NULL
first	NULL
published	NULL
J.	NULL
Viror	NULL
.	NULL

CD4*	NULL
T-cell	NULL
clone	NULL
reactive	NULL
with	NULL
VP16	NULL
.	NULL

VP16	NULL
is	NULL
an	NULL
abundant	NULL
virion	NULL
tegument	NULL
protein	NULL
,	NULL
present	NULL
as	NULL
400	NULL
to	NULL
2,000	NULL
molecules	NULL
per	NULL
virion	NULL
(	NULL
6	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
hypothesis	NULL
that	NULL
preformed	NULL
virion	NULL
proteins	NULL
,	NULL
rather	NULL
than	NULL
endogenously	NULL
synthesized	NULL
viral	NULL
proteins	NULL
,	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
recognized	NULL
by	NULL
the	NULL
CD4*	NULL
T-cell	NULL
response	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
predicted	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
VP16	NULL
of	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
are	NULL
86	NULL
%	NULL
identical	NULL
,	NULL
with	NULL
maximal	NULL
divergence	NULL
in	NULL
the	NULL
carboxy-terminal	NULL
activation	NULL
subdomain	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Type-specific	NULL
T-cell	NULL
clone	NULL
1¥.B.25	NULL
is	NULL
restricted	NULL
by	NULL
HLA	NULL
DQ2	NULL
,	NULL
as	NULL
determined	NULL
from	NULL
data	NULL
from	NULL
partially	NULL
HLA	NULL
matched	NULL
allogeneic	NULL
APC	NULL
and	NULL
inhibition	NULL
of	NULL
proliferative	NULL
responses	NULL
to	NULL
autologous	NULL
APC	NULL
by	NULL
various	NULL
anti-HLA	NULL
class	NULL
II	NULL
MAbs	NULL
(	NULL
Table	NULL
6	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
proliferative	NULL
response	NULL
to	NULL
allogeneic	NULL
,	NULL
HLA	NULL
DQ2-bearing	NULL
APC	NULL
plus	NULL
antigen	NULL
by	NULL
anti-HLA	NULL
DQ	NULL
MAb	NULL
would	NULL
also	NULL
be	NULL
expected	NULL
;	NULL
this	NULL
confirmatory	NULL
experiment	NULL
and	NULL
identification	NULL
of	NULL
further	NULL
HLA	NULL
restriction	NULL
elements	NULL
of	NULL
additional	NULL
T-cell	NULL
clones	NULL
are	NULL
under	NULL
way	NULL
.	NULL

The	NULL
naturally	NULL
processed	NULL
epitope	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
most	NULL
likely	NULL
includes	NULL
the	NULL
overlap	NULL
region	NULL
,	NULL
amino	NULL
acids	NULL
430	NULL
to	NULL
439	NULL
,	NULL
shared	NULL
by	NULL
the	NULL
two	NULL
antigenic	NULL
peptides	NULL
425	NULL
to	NULL
439	NULL
and	NULL
430	NULL
to	NULL
444	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
overlap	NULL
region	NULL
(	NULL
EEVDMTPADA	NULL
)	NULL
shares	NULL
negatively	NULL
charged	NULL
amino	NULL
acids	NULL
at	NULL
positions	NULL
1	NULL
and	NULL
9	NULL
and	NULL
alanine	NULL
at	NULL
position	NULL
8	NULL
with	NULL
positions	NULL
2	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
of	NULL
the	NULL
HLA	NULL
DQ2-restricted	NULL
peptide	NULL
IDVWLGGLAE	NULL
NSLP	NULL
(	NULL
human	NULL
thyroid	NULL
peroxidase	NULL
positions	NULL
632	NULL
to	NULL
645	NULL
[	NULL
14	NULL
,	NULL
21	NULL
]	NULL
)	NULL
.	NULL

A	NULL
low	NULL
proportion	NULL
(	NULL
5	NULL
of	NULL
47	NULL
[	NULL
11	NULL
%	NULL
]	NULL
)	NULL
of	NULL
lesion-derived	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
were	NULL
specific	NULL
for	NULL
the	NULL
abundant	NULL
membrane	NULL
glycoprotein	NULL
gB	NULL
,	NULL
gC	NULL
,	NULL
or	NULL
gD	NULL
.	NULL

Several	NULL
factors	NULL
may	NULL
have	NULL
limited	NULL
detection	NULL
of	NULL
T-cell	NULL
clones	NULL
with	NULL
these	NULL
specificities	NULL
.	NULL

First	NULL
,	NULL
the	NULL
recombinant	NULL
gB2	NULL
and	NULL
gD2	NULL
molecules	NULL
used	NULL
in	NULL
this	NULL
study	NULL
have	NULL
C-terminal	NULL
deletions	NULL
;	NULL
the	NULL
reagents	NULL
include	NULL
79	NULL
and	NULL
82	NULL
%	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
the	NULL
native	NULL
proteins	NULL
after	NULL
cleavage	NULL
of	NULL
N-terminal	NULL
signal	NULL
sequences	NULL
(	NULL
44	NULL
,	NULL
55	NULL
)	NULL
.	NULL

T-cell	NULL
clones	NULL
reactive	NULL
with	NULL
whole	NULL
HSV	NULL
antigens	NULL
would	NULL
be	NULL
scored	NULL
as	NULL
negative	NULL
for	NULL
gB2	NULL
or	NULL
gD2	NULL
if	NULL
they	NULL
were	NULL
specific	NULL
for	NULL
epitopes	NULL
not	NULL
included	NULL
in	NULL
the	NULL
recombinant	NULL
soluble	NULL
glycopro-teins	NULL
.	NULL

Second	NULL
,	NULL
only	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clones	NULL
reacting	NULL
with	NULL
RS1G25	NULL
but	NULL
not	NULL
RS1G31	NULL
antigens	NULL
were	NULL
screened	NULL
for	NULL
gC2	NULL
reactivity	NULL
;	NULL
type-common	NULL
,	NULL
gC-specific	NULL
T-cell	NULL
clones	NULL
would	NULL
be	NULL
missed	NULL
by	NULL
this	NULL
method	NULL
.	NULL

However	NULL
,	NULL
the	NULL
31	NULL
%	NULL
divergence	NULL
between	NULL
the	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
gC1	NULL
and	NULL
gC2	NULL
(	NULL
41	NULL
)	NULL
makes	NULL
it	NULL
likely	NULL
that	NULL
most	NULL
T-cell	NULL
epitopes	NULL
of	NULL
HSV	NULL
gC	NULL
will	NULL
be	NULL
type	NULL
specific	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
glycoprotein	NULL
antigen	NULL
used	NULL
in	NULL
proliferation	NULL
assays	NULL
may	NULL
have	NULL
been	NULL
suboptimal	NULL
for	NULL
some	NULL
T-cell	NULL
clones	NULL
,	NULL
although	NULL
a	NULL
2-ug/ml	NULL
concentration	NULL
of	NULL
HSV	NULL
gB	NULL
,	NULL
gC	NULL
,	NULL
and	NULL
gD	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
optimal	NULL
for	NULL
eliciting	NULL
proliferative	NULL
responses	NULL
from	NULL
bulk	NULL
PBMC	NULL
and	NULL
PBMC-derived	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
(	NULL
43	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Even	NULL
allowing	NULL
for	NULL
these	NULL
potential	NULL
limiting	NULL
factors	NULL
,	NULL
however	NULL
,	NULL
there	NULL
is	NULL
still	NULL
a	NULL
marked	NULL
contrast	NULL
between	NULL
the	NULL
previously	NULL
reported	NULL
finding	NULL
that	NULL
most	NULL
PBMC-derived	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
are	NULL
specific	NULL
for	NULL
gB	NULL
or	NULL
gD	NULL
(	NULL
52	NULL
)	NULL
and	NULL
the	NULL
results	NULL
of	NULL
the	NULL
present	NULL
study	NULL
with	NULL
lesion-derived	NULL
T-cell	NULL
clones	NULL
.	NULL

The	NULL
large	NULL
size	NULL
of	NULL
the	NULL
HSV	NULL
genome	NULL
(	NULL
33	NULL
)	NULL
and	NULL
the	NULL
diverse	NULL
peptides	NULL
bound	NULL
to	NULL
various	NULL
human	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
(	NULL
9	NULL
)	NULL
lead	NULL
to	NULL
the	NULL
prediction	NULL
that	NULL
a	NULL
large	NULL
number	NULL
of	NULL
human	NULL
CD4*	NULL
epitopes	NULL
are	NULL
present	NULL
with	NULL
HSV-2	NULL
.	NULL

Considerable	NULL
diversity	NULL
was	NULL
detected	NULL
among	NULL
the	NULL
antigens	NULL
recognized	NULL
by	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
recovered	NULL
from	NULL
individual	NULL
patients	NULL
.	NULL

For	NULL
example	NULL
,	NULL
a	NULL
minimum	NULL
of	NULL
six	NULL
different	NULL
specificities	NULL
were	NULL
detected	NULL
for	NULL
patient	NULL
5	NULL
:	NULL
gB2	NULL
,	NULL
at	NULL
least	NULL
one	NULL
HSV-2	NULL
type-specific	NULL
epitope	NULL
encoded	NULL
by	NULL
HSV-2	NULL
DNA	NULL
present	NULL
within	NULL
each	NULL
of	NULL
the	NULL
three	NULL
IRV	NULL
(	NULL
RH1G7	NULL
,	NULL
RS1G31	NULL
,	NULL
and	NULL
R7015	NULL
)	NULL
,	NULL
at	NULL
least	NULL
one	NULL
type-common	NULL
epitope	NULL
in	NULL
addition	NULL
to	NULL
gB2	NULL
,	NULL
and	NULL
at	NULL
least	NULL
one	NULL
HSV-2	NULL
type-specific	NULL
epitope	NULL
encoded	NULL
by	NULL
HSV-2	NULL
gene	NULL
sequence	NULL
(	NULL
s	NULL
)	NULL
not	NULL
contained	NULL
within	NULL
the	NULL
panel	NULL
of	NULL
IRV	NULL
.	NULL

The	NULL
overall	NULL
detection	NULL
of	NULL
at	NULL
least	NULL
10	NULL
T-cell	NULL
epitopes	NULL
Vor	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
recognized	NULL
by	NULL
lesion-infiltrating	NULL
HSV-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
provides	NULL
a	NULL
minimum	NULL
estimate	NULL
of	NULL
the	NULL
diversity	NULL
of	NULL
viral	NULL
epitopes	NULL
because	NULL
of	NULL
the	NULL
small	NULL
number	NULL
of	NULL
patients	NULL
studied	NULL
,	NULL
the	NULL
limited	NULL
availability	NULL
of	NULL
purified	NULL
viral	NULL
proteins	NULL
,	NULL
and	NULL
,	NULL
for	NULL
HSV-2	NULL
type-specific	NULL
T-cell	NULL
clones	NULL
,	NULL
the	NULL
incomplete	NULL
coverage	NULL
and	NULL
crude	NULL
mapping	NULL
of	NULL
the	NULL
HSV-2	NULL
genome	NULL
provided	NULL
by	NULL
the	NULL
current	NULL
panel	NULL
of	NULL
IRV	NULL
.	NULL

We	NULL
plan	NULL
to	NULL
combine	NULL
epitope	NULL
mapping	NULL
with	NULL
additional	NULL
IRV	NULL
and	NULL
determination	NULL
of	NULL
individual	NULL
clonal	NULL
HLA	NULL
restriction	NULL
elements	NULL
with	NULL
consensus	NULL
motifs	NULL
for	NULL
HLA	NULL
class	NULL
II-binding	NULL
peptides	NULL
(	NULL
9	NULL
)	NULL
and	NULL
HSV	NULL
sequence	NULL
data	NULL
to	NULL
define	NULL
epitopes	NULL
at	NULL
the	NULL
peptide	NULL
level	NULL
.	NULL

The	NULL
biological	NULL
roles	NULL
of	NULL
lesion-infiltrating	NULL
antigen-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
resolution	NULL
of	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
are	NULL
not	NULL
known	NULL
.	NULL

Patients	NULL
with	NULL
deficiencies	NULL
of	NULL
CD4*	NULL
cell	NULL
function	NULL
,	NULL
such	NULL
as	NULL
advanced	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
,	NULL
have	NULL
delayed	NULL
and	NULL
incomplete	NULL
resolution	NULL
of	NULL
recurrent	NULL
HSV-2	NULL
infection	NULL
(	NULL
46	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
gC-	NULL
and	NULL
gD-specific	NULL
clones	NULL
described	NULL
above	NULL
,	NULL
only	NULL
one	NULL
additional	NULL
HLA-restricted	NULL
,	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
with	NULL
CTL	NULL
activity	NULL
was	NULL
detected	NULL
among	NULL
the	NULL
47	NULL
T-cell	NULL
clones	NULL
described	NULL
in	NULL
this	NULL
study	NULL
(	NULL
3/47	NULL
=	NULL
6	NULL
%	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
30	NULL
to	NULL
80	NULL
%	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
donor	NULL
,	NULL
of	NULL
PBMC-derived	NULL
HSV-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
obtained	NULL
with	NULL
secondary	NULL
in	NULL
vitro	NULL
stimulation	NULL
have	NULL
had	NULL
CTL	NULL
activity	NULL
(	NULL
52	NULL
)	NULL
.	NULL

The	NULL
apparent	NULL
difference	NULL
may	NULL
be	NULL
related	NULL
to	NULL
culture	NULL
conditions	NULL
,	NULL
as	NULL
progressive	NULL
increases	NULL
in	NULL
apparent	NULL
CTL	NULL
activity	NULL
with	NULL
in	NULL
vitro	NULL
restimulation	NULL
with	NULL
antigen	NULL
have	NULL
been	NULL
described	NULL
for	NULL
human	NULL
CD4*	NULL
clones	NULL
specific	NULL
for	NULL
other	NULL
viruses	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Additional	NULL
potential	NULL
effector	NULL
functions	NULL
include	NULL
secretion	NULL
of	NULL
lymphokines	NULL
with	NULL
antiviral	NULL
or	NULL
immunomodulatory	NULL
activity	NULL
,	NULL
including	NULL
gamma	NULL
interferon	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
,	NULL
and	NULL
B-cell	NULL
helper	NULL
activity	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Studies	NULL
of	NULL
lymphokines	NULL
produced	NULL
in	NULL
situ	NULL
in	NULL
HSV	NULL
lesions	NULL
and	NULL
in	NULL
vitro	NULL
by	NULL
HSV-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
are	NULL
under	NULL
way	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
CD4*	NULL
T	NULL
cells	NULL
present	NULL
within	NULL
human	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
recognize	NULL
a	NULL
diverse	NULL
set	NULL
of	NULL
type-common	NULL
and	NULL
HSV-2	NULL
type-specific	NULL
antigens	NULL
.	NULL

T-cell	NULL
clones	NULL
specific	NULL
for	NULL
gB	NULL
and	NULL
gD	NULL
have	NULL
been	NULL
detected	NULL
,	NULL
extending	NULL
observations	NULL
with	NULL
PBMC-derived	NULL
T-lymphocyte	NULL
clones	NULL
.	NULL

Human	NULL
T-cell	NULL
clones	NULL
specific	NULL
for	NULL
gC	NULL
and	NULL
the	NULL
virion	NULL
tegument	NULL
protein	NULL
VP16	NULL
have	NULL
been	NULL
detected	NULL
for	NULL
the	NULL
first	NULL
time	NULL
,	NULL
and	NULL
at	NULL
least	NULL
five	NULL
additional	NULL
HSV-2	NULL
type-specific	NULL
antigens	NULL
have	NULL
been	NULL
defined	NULL
by	NULL
using	NULL
patterns	NULL
of	NULL
reactivity	NULL
with	NULL
HSV-1	NULL
x	NULL
HSV-2	NULL
IRV	NULL
.	NULL

In	NULL
one	NULL
patient	NULL
for	NULL
which	NULL
two	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
have	NULL
been	NULL
studied	NULL
,	NULL
a	NULL
T-cell	NULL
clone	NULL
reactive	NULL
with	NULL
a	NULL
HSV-2	NULL
type-specific	NULL
antigen	NULL
mapping	NULL
to	NULL
the	NULL
same	NULL
region	NULL
of	NULL
the	NULL
HSV-2	NULL
genome	NULL
(	NULL
approximately	NULL
0.30	NULL
to	NULL
0.46	NULL
map	NULL
units	NULL
)	NULL
was	NULL
recovered	NULL
from	NULL
both	NULL
lesions	NULL
.	NULL

Study	NULL
of	NULL
additional	NULL
lesions	NULL
and	NULL
genetic	NULL
analysis	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
genes	NULL
of	NULL
T-cell	NULL
clones	NULL
derived	NULL
from	NULL
sequential	NULL
HSV	NULL
lesions	NULL
may	NULL
determine	NULL
whether	NULL
clonotypic	NULL
T	NULL
cells	NULL
participate	NULL
in	NULL
the	NULL
host	NULL
reaction	NULL
to	NULL
serial	NULL
HSV	NULL
recurrences	NULL
within	NULL
an	NULL
individual	NULL
pa-tient	NULL
.	NULL

Continued	NULL
work	NULL
on	NULL
the	NULL
diversity	NULL
and	NULL
antigenic	NULL
specificity	NULL
of	NULL
the	NULL
human	NULL
CD4*	NULL
response	NULL
to	NULL
HSV	NULL
may	NULL
further	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
processes	NULL
by	NULL
which	NULL
the	NULL
host	NULL
controls	NULL
human	NULL
recurrent	NULL
herpes	NULL
simplex	NULL
infection	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
Specimens	NULL
were	NULL
collected	NULL
by	NULL
Gail	NULL
Barnum	NULL
,	NULL
Michael	NULL
Remington	NULL
,	NULL
Peter	NULL
Tretheway	NULL
,	NULL
and	NULL
Mary	NULL
Shaughnessy	NULL
.	NULL

Invaluable	NULL
technical	NULL
assistance	NULL
was	NULL
given	NULL
by	NULL
Annette	NULL
Peck	NULL
and	NULL
Hiyam	NULL
Abbo	NULL
.	NULL

HLA	NULL
typing	NULL
was	NULL
performed	NULL
by	NULL
Brenda	NULL
Nisperos	NULL
and	NULL
John	NULL
Hansen	NULL
at	NULL
the	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
Wash.	NULL
Bernard	NULL
Roizman	NULL
and	NULL
Patricia	NULL
Spear	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
provided	NULL
recombinant	NULL
HSV	NULL
strains	NULL
.	NULL

David	NULL
B.	NULL
Lewis	NULL
and	NULL
Tom	NULL
Cotner	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
provided	NULL
MAbs	NULL
and	NULL
helpful	NULL
advice	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grants	NULL
Al31448	NULL
and	NULL
AI34616	NULL
(	NULL
D.M.K	NULL
.	NULL
)	NULL

,	NULL
AI20381	NULL
(	NULL
L.C	NULL
.	NULL
)	NULL

,	NULL
and	NULL
AI27323	NULL
(	NULL
S.J.T	NULL
.	NULL
)	NULL

and	NULL
by	NULL
a	NULL
Junior	NULL
Faculty	NULL
Research	NULL
Award	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
(	NULL
S.J.T	NULL
.	NULL
)	NULL

.	NULL

HUMAN	NULL
LESIONAL	NULL
HSV-SPECIFIC	NULL
CD4*	NULL
T	NULL
CELLS	NULL
2809	NULL
REFERENCES	NULL
1	NULL
.	NULL

Ashley	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Critchlow	NULL
,	NULL
M.	NULL
Shurtleff	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1988	NULL
.	NULL

Differential	NULL
effect	NULL
of	NULL
systemic	NULL
acyclovir	NULL
treatment	NULL
of	NULL
genital	NULL
HSV-2	NULL
infections	NULL
on	NULL
antibody	NULL
responses	NULL
to	NULL
individual	NULL
HSV-2	NULL
proteins	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

24:309-320	NULL
.	NULL

2	NULL
.	NULL

Ashley	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
J.	NULL
Militoni	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
A.	NULL
Nahmias	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1988	NULL
.	NULL

Comparison	NULL
of	NULL
Western	NULL
blot	NULL
(	NULL
immunoblot	NULL
)	NULL
and	NULL
glycoprotein	NULL
G-specific	NULL
immunoblot	NULL
for	NULL
detecting	NULL
antibodies	NULL
to	NULL
herpes	NULL
simplex	NULL
types	NULL
1	NULL
and	NULL
2	NULL
in	NULL
human	NULL
sera	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

26:662-667	NULL
.	NULL

3	NULL
.	NULL

Barker	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
three	NULL
genes	NULL
nonessential	NULL
for	NULL
growth	NULL
in	NULL
cell	NULL
culture	NULL
near	NULL
the	NULL
right	NULL
terminus	NULL
of	NULL
the	NULL
unique	NULL
sequences	NULL
of	NULL
long	NULL
component	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Virology	NULL
177:684-691	NULL
.	NULL

4	NULL
.	NULL

Barker	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
unique	NULL
sequence	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
1	NULL
L	NULL
component	NULL
contains	NULL
an	NULL
additional	NULL
translated	NULL
open	NULL
reading	NULL
frame	NULL
designated	NULL
UL49.5	NULL
.	NULL

Virology	NULL
66	NULL
:	NULL
562-566	NULL
.	NULL

5	NULL
.	NULL

Barnett	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
A.	NULL
Dolan	NULL
,	NULL
E.	NULL
A.	NULL
R.	NULL
Telford	NULL
,	NULL
A.	NULL
J.	NULL
Davison	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
McGeoch	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
herpes	NULL
simplex	NULL
virus	NULL
gene	NULL
(	NULL
ULA9A	NULL
)	NULL
encodes	NULL
a	NULL
putative	NULL
membrane	NULL
protein	NULL
with	NULL
counterparts	NULL
in	NULL
other	NULL
herpesviruses	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

73:2167-2171	NULL
.	NULL

6	NULL
.	NULL

Batterson	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
,	NULL
.	NULL

1983	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus-associated	NULL
factor	NULL
responsible	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
genes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

46:371-377	NULL
.	NULL

7	NULL
.	NULL

Brodsky	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
and	NULL
L.	NULL
E.	NULL
Guagliardi	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
cell	NULL
biology	NULL
and	NULL
antigen	NULL
processing	NULL
and	NULL
presentation	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9:707-	NULL
8	NULL
.	NULL

Burke	NULL
,	NULL
R.	NULL
L.	NULL
1991	NULL
.	NULL

Development	NULL
of	NULL
a	NULL
herpes	NULL
simplex	NULL
virus	NULL
subunit	NULL
glycoprotein	NULL
vaccine	NULL
for	NULL
prophylactic	NULL
and	NULL
therapeutic	NULL
use	NULL
.	NULL

Rev	NULL
.	NULL

Infect	NULL
.	NULL

Dis	NULL
.	NULL

13	NULL
:	NULL
$	NULL
906-S911	NULL
.	NULL

9	NULL
.	NULL

Chicz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
R.	NULL
G.	NULL
Urban	NULL
,	NULL
J.	NULL
C.	NULL
Gorga	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

A.	NULL
Vignali	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Strominger	NULL
.	NULL

1993	NULL
.	NULL

Specificity	NULL
and	NULL
promiscuity	NULL
among	NULL
naturally	NULL
processed	NULL
peptides	NULL
bound	NULL
to	NULL
HLA-DR	NULL
alleles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:27-47	NULL
.	NULL

10	NULL
.	NULL

Conley	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
P.	NULL
C.	NULL
Jones	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1981	NULL
.	NULL

Molecular	NULL
genetics	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

VIL	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
temperature-sensitive	NULL
mutant	NULL
produced	NULL
by	NULL
in	NULL
vitro	NULL
mutagen-esis	NULL
and	NULL
defective	NULL
in	NULL
DNA	NULL
synthesis	NULL
and	NULL
accumulation	NULL
of	NULL
+	NULL
polypeptides	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

37:191-206	NULL
.	NULL

11	NULL
.	NULL

Cress	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Triezenberg	NULL
.	NULL

1991	NULL
.	NULL

Nucleotide	NULL
and	NULL
deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
virion	NULL
protein	NULL
16	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Gene	NULL
103:235-238	NULL
.	NULL

12	NULL
.	NULL

Cunningham	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Noble	NULL
.	NULL

1989	NULL
.	NULL

Role	NULL
of	NULL
keratinocytes	NULL
in	NULL
human	NULL
recurrent	NULL
herpetic	NULL
lesions	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

83:490-496	NULL
.	NULL

13	NULL
.	NULL

Cunningham	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
R.	NULL
R.	NULL
Turner	NULL
,	NULL
A.	NULL
C.	NULL
Miller	NULL
,	NULL
M.	NULL
F.	NULL
Para	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Merigan	NULL
,	NULL
1985	NULL
.	NULL

Evolution	NULL
of	NULL
recurrent	NULL
herpes	NULL
simplex	NULL
lesions	NULL
:	NULL
an	NULL
immunohistologic	NULL
study	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

75:226-233	NULL
.	NULL

14	NULL
.	NULL

Dayan	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
M.	NULL
Londei	NULL
,	NULL
A.	NULL
E.	NULL
Corcoran	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

Autoantigen	NULL
recognition	NULL
by	NULL
thyroid-infiltrating	NULL
T	NULL
cells	NULL
in	NULL
Graves	NULL
disease	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:7415-7419	NULL
.	NULL

15	NULL
.	NULL

Debroy	NULL
,	NULL
C.	NULL
1990	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
type	NULL
2	NULL
syn	NULL
gene	NULL
that	NULL
causes	NULL
cell	NULL
fusion	NULL
.	NULL

Gene	NULL
88:275-277	NULL
.	NULL

16	NULL
.	NULL

Elliott	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Meredith	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
tegument	NULL
protein	NULL
VP22	NULL
is	NULL
encoded	NULL
by	NULL
gene	NULL
ULA9	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

73:723-736	NULL
.	NULL

17	NULL
.	NULL

Fleischer	NULL
,	NULL
B	NULL
.	NULL

1984	NULL
.	NULL

Acquisition	NULL
of	NULL
specific	NULL
cytotoxic	NULL
activity	NULL
by	NULL
human	NULL
T4+	NULL
lymphocytes	NULL
in	NULL
culture	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
308:365-367	NULL
.	NULL

18	NULL
.	NULL

Hendricks	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
T.	NULL
M.	NULL
Tumpey	NULL
,	NULL
and	NULL
A.	NULL
Finnegan	NULL
.	NULL

1992	NULL
.	NULL

IFN-t	NULL
and	NULL
IL-2	NULL
are	NULL
protective	NULL
in	NULL
the	NULL
skin	NULL
but	NULL
pathologic	NULL
in	NULL
the	NULL
corneas	NULL
of	NULL
HSV-1-infected	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:3023-3028	NULL
.	NULL

19	NULL
.	NULL

Ho	NULL
,	NULL
M.	NULL
1990	NULL
.	NULL

Interferon	NULL
as	NULL
an	NULL
agent	NULL
against	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

95:158S-1608	NULL
.	NULL

20	NULL
.	NULL

Hudson	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
C.	NULL
Hay	NULL
,	NULL
1989	NULL
.	NULL

Practical	NULL
immunology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Blackwell	NULL
Scientific	NULL
Publications	NULL
,	NULL
Oxford	NULL
.	NULL

21	NULL
.	NULL

Kimura	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Kotani	NULL
,	NULL
O.	NULL
W.	NULL
McBride	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
thyroid	NULL
peroxidase	NULL
:	NULL
complete	NULL
cDNA	NULL
and	NULL
protein	NULL
sequence	NULL
,	NULL
chromosome	NULL
mapping	NULL
,	NULL
and	NULL
identification	NULL
of	NULL
two	NULL
alternatively	NULL
spliced	NULL
mRNAs	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:5555-5559	NULL
.	NULL

22	NULL
.	NULL

Kit	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Kit	NULL
,	NULL
H.	NULL
Qavi	NULL
,	NULL
D.	NULL
Trkula	NULL
,	NULL
and	NULL
H.	NULL
Otsuka	NULL
.	NULL

1983	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
HSV-2	NULL
)	NULL
thymidine	NULL
kinase	NULL
gene	NULL
and	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
thymidine	NULL
kinase	NULL
polypeptide	NULL
and	NULL
its	NULL
comparison	NULL
with	NULL
the	NULL
HSV-1	NULL
2810	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

KOELLE	NULL
ET	NULL
AL	NULL
.	NULL

thymidine	NULL
kinase	NULL
gene	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
741:158	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
H.	NULL
Abbo	NULL
,	NULL
A.	NULL
Peck	NULL
,	NULL
K.	NULL
Ziegweid	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

Direct	NULL
recovery	NULL
of	NULL
HSV	NULL
-specific	NULL
T	NULL
lymphocyte	NULL
clones	NULL
from	NULL
human	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Leung	NULL
,	NULL
K.	NULL
N.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Nash	NULL
,	NULL
D.	NULL
Y.	NULL
Sia	NULL
,	NULL
and	NULL
P.	NULL
Wildy	NULL
.	NULL

1984	NULL
.	NULL

Clonal	NULL
analysis	NULL
of	NULL
T-cell	NULL
responses	NULL
to	NULL
herpes	NULL
simplex	NULL
virus	NULL
:	NULL
isolation	NULL
,	NULL
characterization	NULL
and	NULL
antiviral	NULL
properties	NULL
of	NULL
an	NULL
antigen-specific	NULL
helper	NULL
T-cell	NULL
clone	NULL
.	NULL

Immunology	NULL
53:623-633	NULL
.	NULL

McGeoch	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
C.	NULL
Cunningham	NULL
,	NULL
G.	NULL
Mcintyre	NULL
,	NULL
and	NULL
A.	NULL
Dolan	NULL
.	NULL

1991	NULL
.	NULL

Comparative	NULL
sequence	NULL
analysis	NULL
of	NULL
the	NULL
long	NULL
repeat	NULL
regions	NULL
and	NULL
adjoining	NULL
parts	NULL
of	NULL
the	NULL
long	NULL
unique	NULL
regions	NULL
in	NULL
the	NULL
genomes	NULL
of	NULL
herpes	NULL
simplex	NULL
viruses	NULL
types	NULL
1	NULL
and	NULL
2	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:3057-3075	NULL
.	NULL

McGeoch	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
M.	NULL
A.	NULL
Dalrymple	NULL
,	NULL
A.	NULL
J.	NULL
Davison	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
complete	NULL
DNA	NULL
sequence	NULL
of	NULL
the	NULL
long	NULL
unique	NULL
region	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

69:1531-1574	NULL
.	NULL

Moretta	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Pantaleo	NULL
,	NULL
L.	NULL
Moretta	NULL
,	NULL
J.-C.	NULL
Cerottini	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Mingari	NULL
.	NULL

1983	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
the	NULL
clonogenic	NULL
potential	NULL
of	NULL
every	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cell	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

157:743-754	NULL
.	NULL

Nash	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
Jayasuriya	NULL
,	NULL
J.	NULL
Phelan	NULL
,	NULL
S.	NULL
P.	NULL
Cobbold	NULL
,	NULL
H.	NULL
Waldman	NULL
,	NULL
and	NULL
T.	NULL
Prospero	NULL
.	NULL

1987	NULL
.	NULL

Different	NULL
roles	NULL
for	NULL
the	NULL
L3T4+	NULL
and	NULL
Lyt2+	NULL
T	NULL
cell	NULL
subsets	NULL
in	NULL
the	NULL
control	NULL
of	NULL
an	NULL
acute	NULL
herpes	NULL
simplex	NULL
virus	NULL
infection	NULL
of	NULL
the	NULL
skin	NULL
and	NULL
nervous	NULL
system	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

68:825-833	NULL
.	NULL

O'Hare	NULL
,	NULL
P.	NULL
1992	NULL
.	NULL

Targets	NULL
for	NULL
antiviral	NULL
chemotherapy	NULL
:	NULL
herpes	NULL
simplex	NULL
virus	NULL
regulatory	NULL
protein	NULL
,	NULL
Vmw65	NULL
.	NULL

Antiviral	NULL
Chem	NULL
.	NULL

Che-mother	NULL
.	NULL

2:1-7	NULL
.	NULL

Olivo	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
N.	NULL
J.	NULL
Nelson	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Challberg	NULL
.	NULL

1989	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
gene	NULL
products	NULL
required	NULL
for	NULL
DNA	NULL
replication	NULL
:	NULL
identification	NULL
and	NULL
overexpression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:196-204	NULL
.	NULL

Para	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
K.	NULL
M.	NULL
Zezulak	NULL
,	NULL
A.	NULL
J.	NULL
Conley	NULL
,	NULL
M.	NULL
Weinberger	NULL
,	NULL
K.	NULL
Snitzer	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Spear	NULL
.	NULL

1983	NULL
.	NULL

Use	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
two	NULL
75,000-molecular-weight	NULL
glycoproteins	NULL
specified	NULL
by	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
in	NULL
glycoprotein	NULL
identification	NULL
and	NULL
gene	NULL
mapping	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

45:1223-1227	NULL
.	NULL

Purves	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
D.	NULL
Spector	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
protein	NULL
kinase	NULL
encoded	NULL
by	NULL
the	NULL
US3	NULL
gene	NULL
mediates	NULL
posttranslational	NULL
modification	NULL
of	NULL
the	NULL
phosphoprotein	NULL
encoded	NULL
by	NULL
the	NULL
UL34	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5757-5764	NULL
.	NULL

Roizman	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Sears	NULL
.	NULL

1990	NULL
.	NULL

Herpes	NULL
simplex	NULL
viruses	NULL
and	NULL
their	NULL
replication	NULL
.	NULL

p.	NULL
1795-1841	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
and	NULL
D.	NULL
M.	NULL
Knipe	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

vol	NULL
.	NULL

2	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Ltd.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Roizman	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
M.	NULL
Tognon	NULL
.	NULL

1983	NULL
.	NULL

Restriction	NULL
endonuclease	NULL
patterns	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
DNA	NULL
:	NULL
application	NULL
to	NULL
diagnosis	NULL
and	NULL
molecular	NULL
epidemiology	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

104:274-286	NULL
.	NULL

Royston	NULL
,	NULL
I.	NULL
,	NULL
M.	NULL
B.	NULL
Omary	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Trowbridge	NULL
.	NULL

1981	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
to	NULL
a	NULL
human	NULL
T-cell	NULL
antigen	NULL
and	NULL
Ia-like	NULL
antigen	NULL
in	NULL
the	NULL
characterization	NULL
of	NULL
lymphoid	NULL
leukemia	NULL
.	NULL

Transplant	NULL
.	NULL

Proc	NULL
.	NULL

13:761-766	NULL
.	NULL

Sadowski	NULL
,	NULL
I.	NULL
,	NULL
J.	NULL
Ma	NULL
,	NULL
S.	NULL
Triezenberg	NULL
,	NULL
and	NULL
M.	NULL
Ptashne	NULL
.	NULL

1988	NULL
.	NULL

Gal4-VP16	NULL
is	NULL
an	NULL
unusually	NULL
potent	NULL
transcriptional	NULL
activator	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
335:563-564	NULL
.	NULL

Schmidt	NULL
,	NULL
N.	NULL
J	NULL
.	NULL

1989	NULL
.	NULL

Cell	NULL
culture	NULL
procedures	NULL
for	NULL
diagnostic	NULL
virology	NULL
,	NULL
p.	NULL
57-100	NULL
.	NULL

In	NULL
N.	NULL
J.	NULL
Schmidt	NULL
and	NULL
R.	NULL
W.	NULL
Emmons	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Diagnostic	NULL
procedures	NULL
for	NULL
viral	NULL
,	NULL
rickettsial	NULL
and	NULL
chlamydial	NULL
infec-tions	NULL
,	NULL
6th	NULL
ed	NULL
.	NULL

American	NULL
Public	NULL
Health	NULL
Association	NULL
,	NULL
Washington	NULL
,	NULL
D.C.	NULL
37a.Shen	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
G.	NULL
Reddy	NULL
,	NULL
R.	NULL
Pichyangkura	NULL
,	NULL
and	NULL
S.	NULL
Triezenberg	NULL
.	NULL

38	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Smith	NULL
,	NULL
L	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
R.	NULL
Petty	NULL
,	NULL
P.	NULL
Parham	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
McConnell	NULL
.	NULL

1982	NULL
.	NULL

Cell	NULL
surface	NULL
properties	NULL
of	NULL
HLA	NULL
antigens	NULL
in	NULL
Epstein-Barr	NULL
virus-transformed	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
79:608-612	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

Spits	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Borst	NULL
,	NULL
M.	NULL
Giphart	NULL
,	NULL
J.	NULL
Cougan	NULL
,	NULL
C.	NULL
Terhorst	NULL
,	NULL
and	NULL
T.	NULL
E.	NULL
De	NULL
Vries	NULL
.	NULL

1984	NULL
.	NULL

HLA-DC	NULL
antigens	NULL
can	NULL
serve	NULL
as	NULL
recognition	NULL
elements	NULL
for	NULL
human	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

14:299-304	NULL
.	NULL

Spruance	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
S.	NULL
Chow	NULL
.	NULL

1980	NULL
.	NULL

Pathogenesis	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
in	NULL
cultures	NULL
of	NULL
epidermal	NULL
cells	NULL
from	NULL
subjects	NULL
with	NULL
frequent	NULL
recurrences	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

142:671-675	NULL
.	NULL

Swain	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
R.	NULL
W.	NULL
Peet	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Galloway	NULL
.	NULL

1985	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
glycoprotein	NULL
C	NULL
and	NULL
comparison	NULL
with	NULL
the	NULL
type	NULL
1	NULL
counterpart	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

53:561-569	NULL
.	NULL

Tigges	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
D.	NULL
M.	NULL
Koelle	NULL
,	NULL
K.	NULL
Hartog	NULL
,	NULL
R.	NULL
E.	NULL
Sekulovich	NULL
,	NULL
L.	NULL
Corey	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Burke	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
CD8*	NULL
herpes	NULL
simplex	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
clones	NULL
recognize	NULL
diverse	NULL
virion	NULL
protein	NULL
antigens	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:1622-1634	NULL
.	NULL

Torseth	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
G.	NULL
H.	NULL
Cohen	NULL
,	NULL
R.	NULL
J.	NULL
Eisenberg	NULL
,	NULL
P.	NULL
W.	NULL
Berman	NULL
,	NULL
L.	NULL
A.	NULL
Lasky	NULL
,	NULL
C.	NULL
P.	NULL
Cerini	NULL
,	NULL
C.	NULL
J.	NULL
Heilman	NULL
,	NULL
S.	NULL
Kerwar	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Merigan	NULL
.	NULL

1987	NULL
.	NULL

Native	NULL
and	NULL
recombinant	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
envelope	NULL
proteins	NULL
induce	NULL
human	NULL
immune	NULL
T-lymphocyte	NULL
responses	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1532-1539	NULL
.	NULL

Watson	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

1983	NULL
.	NULL

DNA	NULL
sequence	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
glycoprotein	NULL
D	NULL
gene	NULL
.	NULL

Gene	NULL
26:307-312	NULL
.	NULL

Weinheimer	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
Boyd	NULL
,	NULL
S.	NULL
K.	NULL
Durham	NULL
,	NULL
J.	NULL
L.	NULL
Resnick	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
O'Boyle	NULL
.	NULL

1992	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
VP16	NULL
open	NULL
reading	NULL
frame	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:258-269	NULL
.	NULL

Whitley	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

Herpes	NULL
simplex	NULL
viruses	NULL
,	NULL
p.	NULL
1843-1887	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
and	NULL
D.	NULL
M.	NULL
Knipe	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Ltd.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Williams	NULL
,	NULL
M.	NULL
V.	NULL
1988	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus-induced	NULL
dUTPase	NULL
:	NULL
target	NULL
site	NULL
for	NULL
antiviral	NULL
chemotherapy	NULL
.	NULL

Virology	NULL
166:262-264	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Inatsuki	NULL
,	NULL
T.	NULL
Horiuchi	NULL
,	NULL
and	NULL
Y.	NULL
Kobayashi	NULL
.	NULL

1991	NULL
.	NULL

Functional	NULL
heterogeneity	NULL
among	NULL
herpes	NULL
simplex	NULL
virus-specific	NULL
human	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:1341-1347	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Inatsuki	NULL
,	NULL
and	NULL
Y.	NULL
Kobayashi	NULL
.	NULL

1988	NULL
.	NULL

Helper	NULL
activity	NULL
in	NULL
antigen-specific	NULL
antibody	NULL
production	NULL
mediated	NULL
by	NULL
CD4+	NULL
human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140:3419-3425	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Y.	NULL
Kobayashi	NULL
.	NULL

1985	NULL
.	NULL

Inhibition	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
replication	NULL
in	NULL
vitro	NULL
by	NULL
human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
and	NULL
natural	NULL
killer	NULL
cell	NULL
clones	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

66:2225-2229	NULL
.	NULL

Yasukawa	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Zarling	NULL
.	NULL

1984	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus-infected	NULL
cells	NULL
.	NULL

I.	NULL
Lysis	NULL
restricted	NULL
by	NULL
HLA	NULL
Class	NULL
II	NULL
MB	NULL
and	NULL
DR	NULL
antigens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

133:422-427	NULL
.	NULL

Zarling	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
A.	NULL
Moran	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
C.	NULL
Pachl	NULL
,	NULL
P.	NULL
W.	NULL
Berman	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Lasky	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
herpes	NULL
simplex	NULL
virus-infected	NULL
cells	NULL
.	NULL

IV	NULL
.	NULL

Recognition	NULL
and	NULL
activation	NULL
by	NULL
cloned	NULL
glycoproteins	NULL
gB	NULL
and	NULL
gD-1	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:4669-4673	NULL
.	NULL

Zezulak	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Spear	NULL
.	NULL

1984	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
structural	NULL
gene	NULL
for	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
counterpart	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
glycoprotein	NULL
C	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
type	NULL
2	NULL
mutant	NULL
which	NULL
does	NULL
not	NULL
express	NULL
this	NULL
glycoprotein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

49:741-747	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
C.	NULL
McKnight	NULL
.	NULL

1993	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
UL46	NULL
and	NULL
UL47	NULL
deletion	NULL
mutants	NULL
lack	NULL
VP11	NULL
and	NULL
VP12	NULL
or	NULL
VP13	NULL
and	NULL
VP14	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
exhibit	NULL
altered	NULL
thymidine	NULL
kinase	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1482-1492	NULL
.	NULL

Zwaagstra	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
W.-C.	NULL
Leung	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
(	NULL
333	NULL
)	NULL
glycoprotein	NULL
gB2	NULL
and	NULL
analysis	NULL
of	NULL
predicted	NULL
antigenic	NULL
sites	NULL
.	NULL

Can	NULL
.	NULL

J.	NULL
Microbiol	NULL
.	NULL

33:879-887	NULL
.	NULL

